CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of 
Bioverativ.  
Page [ADDRESS_705221]  
Waltham, MA [ZIP_CODE]  
TRACKING NUMBER:  997HA402  
PHASE OF DEVELOPMENT:  4 
PROTOCOL TITLE:  A Non -Controlled, Open -Label, Multicenter, Study of Efficacy of 
rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects 
With Inhibitors Undergoing the First ITI Treatment  
EUDRA CT NO:  2017 -000373 -36 
DATE:  11 Jul  2019  
Version 3.0 
Supersedes Version 2.0 dated 09  February 2018 and Version 2.1 dated 02 March 2018 . 
VV-CLIN-0542000 3.0[STUDY_ID_REMOVED]
Protocol 997HA402  Version 3.[ADDRESS_705222] OF ABBREVIATION S................................ ................................ ..................... 12 
3. SYNOP SIS ................................ ................................ ................................ ................. 14 
4. STUDY SCHEMATIC AND SCHEDULE OF ACTIVITI ES ................................ ..19 
4.1. Study Schematic  ................................ ................................ ................................ ......... 19 
4.2. Schedules of Activities  ................................ ................................ ............................... 20 
5. INTRODUCTION  ................................ ................................ ................................ ......31 
5.1. Overview of Immune Tolerance Induction in the Clinical Management of 
Hemophilia A  ................................ ................................ ................................ .............. 31 
5.2. Profile of Previous Experience With rFVIIIFc for Immune Tolerance 
Induction  ................................ ................................ ................................ ..................... 33 
5.2.1.  Previous Nonclinical and Clinical Experience With rFVIIIFc for Immune 
Tolerance Induction  ................................ ................................ ................................ ....33 
5.2.2.  Nonclinical Experience  ................................ ................................ ............................... 33 
5.2.3.  Clinical Experience  ................................ ................................ ................................ .....34 
5.3. Study Rationale  ................................ ................................ ................................ ........... 34 
5.4. Rationale for Dosing Regimen  ................................ ................................ ................... 35 
6. STUDY OBJECTIVES AND  ENDPOINTS  ................................ .............................. 36 
6.1. Primary Objective and Endpoint  ................................ ................................ ................ 36 
6.2. Secondary Objectives and Endpoints  ................................ ................................ ......... 36 
6.3. Exploratory Objectives and Endpoints  ................................ ................................ .......37 
7. STUDY DESIGN  ................................ ................................ ................................ .......38 
7.1. Study Overview  ................................ ................................ ................................ .......... 38 
7.2. Overall Study Duration and Follow -Up ................................ ................................ .....38 
7.2.1.  Screening  ................................ ................................ ................................ .................... 38 
7.2.2.  Immune Tolerance Induction Period  ................................ ................................ .......... 39 
[IP_ADDRESS].  Use of By[CONTACT_71328]  ................................ ................................ ............................ 40 
[IP_ADDRESS].  ITI Outcome  ................................ ................................ ................................ ................ 41 
7.2.3.  Downt itration (Dose Adjustment) Between ITI Treatment and the Tapering 
Period  ................................ ................................ ................................ .......................... 44 
7.2.4.  Tapering Period  ................................ ................................ ................................ .......... 44 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 4 7.2.5.  Follow -Up ................................ ................................ ................................ ................... 45 
7.2.6.  End of Treatment/End of Study  ................................ ................................ .................. 45 
7.2.7.  Final Safety Follow -Up ................................ ................................ .............................. 46 
7.3. Unscheduled Visits  ................................ ................................ ................................ .....46 
7.4. Study Stoppi[INVESTIGATOR_1869]  ................................ ................................ ................................ .46 
7.5. End of Study  ................................ ................................ ................................ ............... 46 
8. SELECTION OF SUBJECTS  ................................ ................................ .................... 47 
8.1. Inclusion Criteria  ................................ ................................ ................................ ........ 47 
8.2. Exclusion Criteria  ................................ ................................ ................................ .......47 
9. ENROLLMENT AND REGIS TRATION, STUDY PROCE DURES  ....................... 49 
9.1. Screening, Enrollment  ................................ ................................ ................................ 49 
9.2. Registration of Subjects  ................................ ................................ .............................. 49 
10. DISCONTINUATION OF S TUDY TREATMENT AND W ITHDRAWAL 
OF SUBJECTS FROM THE  STUDY  ................................ ................................ ........ 50 
11. STUDY TREATMENT  ................................ ................................ .............................. 51 
11.1.  Dosing Regimen and Administration  ................................ ................................ ......... 51 
11.1.1.  Administration of rFVIIIFc  ................................ ................................ ........................ 52 
11.1.2.  Calculation and Recording of Dosing Based on Actual Potency and Dosing 
Based on Nominal Strength  ................................ ................................ ........................ 52 
11.1.3.  Prior and Conc omitant Therapy  ................................ ................................ .................. 53 
11.1.4.  Allowed Concomitant Therapy  ................................ ................................ ................... 53 
11.2.  Compliance  ................................ ................................ ................................ ................. 53 
11.3.  Excluded C oncomitant Therapi[INVESTIGATOR_73910]  ................................ ..................... 53 
12. STUDY TREATMENT MANA GEMENT  ................................ ................................ 55 
12.1.  rFVIIIFc Stability and Storage  ................................ ................................ ................... 55 
12.1.1.  rFVIIIFc Preparation  ................................ ................................ ................................ ..55 
12.1.2.  rFVIIIFc Handling and Disposal  ................................ ................................ ................ 55 
12.2.  rFVIIIFc Accountability  ................................ ................................ ............................. 56 
13. EFFICACY AND PHARMAC OKINETIC ASSESSMENTS  ................................ ...57 
13.1.  Clinical Efficacy Assessments  ................................ ................................ .................... 57 
13.1.1.  Assessment of Inhibitor Titers  ................................ ................................ .................... 57 
13.1.2.  Assessment of Incremental Recovery  ................................ ................................ ......... 57 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 5 [IP_ADDRESS].  FVIII Activity  ................................ ................................ ................................ ............. 57 
[IP_ADDRESS].  Calculations  ................................ ................................ ................................ ................ 58 
13.1.3.  Assessment of rFVIIIFc Half -Life................................ ................................ .............. 59 
[IP_ADDRESS].  Sampling for rFVIIIFc t ½ ................................ ................................ ............................ 59 
[IP_ADDRESS].  Calculations  ................................ ................................ ................................ ................ 60 
13.1.4.  Assessment of Bleeding Epi[INVESTIGATOR_1841]  ................................ ................................ .............. 60 
[IP_ADDRESS].  Definition of a Bleeding Epi[INVESTIGATOR_1865]  ................................ ................................ ............... 60 
[IP_ADDRESS].  Data to Be Captured  ................................ ................................ ................................ ....61 
13.2.  Medical History Assessments  ................................ ................................ ..................... 61 
13.3.  Demography  ................................ ................................ ................................ ............... 62 
13.4.  Pharmacoeconomic Assessments  ................................ ................................ ............... 62 
13.5.  Exploratory Laboratory Assessments  ................................ ................................ ......... 62 
13.5.1.  Assessment of Mechanisms Underlying Inhibitor Development  ............................... 62 
13.5.2.  Anti-rFVIIIFc Antibody Assessment  ................................ ................................ ......... 62 
13.5.3.  Immune Cell Characterization  ................................ ................................ .................... 63 
13.5.4.  Analysis of FVIII Mutation and Human Leukocyte Antigen Allotypi[INVESTIGATOR_007]  ................... 63 
13.5.5.  Future Scientific Research  ................................ ................................ .......................... 64 
14. SAFETY ASSESSMENTS  ................................ ................................ ........................ 65 
14.1.  Clinical Safety Assessments  ................................ ................................ ....................... 65 
14.2.  Laboratory Safety Assessments  ................................ ................................ .................. 65 
14.3.  Vital Signs  ................................ ................................ ................................ .................. 66 
14.4.  Physical Examination  ................................ ................................ ................................ .66 
14.5.  Sample Volumes  ................................ ................................ ................................ ......... 66 
15. SAFETY DEFINITIONS, RECORDING, REPORTING , AND 
RESPONSIBILITIES  ................................ ................................ ................................ .68 
15.1.  Definitions  ................................ ................................ ................................ .................. 68 
15.1.1.  Adverse Event  ................................ ................................ ................................ ............. 68 
15.1.2.  Serious Adverse Event  ................................ ................................ ................................ 69 
15.2. Safety Classifications  ................................ ................................ ................................ ..69 
15.2.1.  Investigator Assessment of Events  ................................ ................................ ............. 69 
15.2.2.  Relationship of Events to Study Treatment  ................................ ................................ 70 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 6 15.2.3.  Severity of Events  ................................ ................................ ................................ .......70 
15.2.4.  Expectedness of Events  ................................ ................................ .............................. 70 
15.3.  Monitoring and Recording Events  ................................ ................................ .............. 71 
15.3.1.  Adverse Events  ................................ ................................ ................................ ........... 71 
15.3.2.  Serious Adverse Events  ................................ ................................ .............................. 71 
15.3.3.  Immediate Reporting of Serious Adverse Events  ................................ ....................... 72 
[IP_ADDRESS].  Deaths  ................................ ................................ ................................ ......................... 72 
15.3.4.  Suspected Unexpected Serious Adverse Reactions  ................................ .................... 72 
15.4.  Procedures for Handling Special Situations  ................................ ............................... 73 
15.4.1.  Contraception  ................................ ................................ ................................ .............. 73 
15.4.2.  Reporting Pregnancy  ................................ ................................ ................................ ..73 
15.4.3.  Overdose  ................................ ................................ ................................ ..................... 73 
15.4.4.  Medical Emergency  ................................ ................................ ................................ ....74 
15.5.  Safety Responsibilities  ................................ ................................ ................................ 74 
15.5.1.  Investigator Responsibilities  ................................ ................................ ....................... 74 
15.5.2.  Sponsor  ................................ ................................ ................................ ....................... 74 
16. STATISTICAL METHODS AND DETERMIN ATION OF SAMPLE SIZE  ........... 75 
16.1.  Sample Size Considerations  ................................ ................................ ....................... 75 
16.2.  Efficacy  ................................ ................................ ................................ ....................... 75 
16.2.1.  Analysis Populations  ................................ ................................ ................................ ..75 
16.2.2.  Methods of Analysis  ................................ ................................ ................................ ...75 
[IP_ADDRESS].  Primary Endpoint Analysis  ................................ ................................ ......................... 75 
[IP_ADDRESS].  Secondary Endpoints Analysis  ................................ ................................ ................... 76 
[IP_ADDRESS].  Pharmacokinetics  ................................ ................................ ................................ ........ 77 
[IP_ADDRESS].  Exposure and Duration of Treatment  ................................ ................................ ......... 77 
[IP_ADDRESS].  Demography and Baseline Disease Characteristics  ................................ .................... 77 
16.3.  Interim Analyses  ................................ ................................ ................................ ......... 77 
16.4.  Safety  ................................ ................................ ................................ .......................... 77 
16.4.1.  Analysis Populations  ................................ ................................ ................................ ..77 
16.4.2. Methods of Analysis  ................................ ................................ ................................ ...77 
[IP_ADDRESS].  Adverse Events  ................................ ................................ ................................ ........... 77 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 7 [IP_ADDRESS].  Clinical Laboratory Results  ................................ ................................ ........................ 77 
[IP_ADDRESS].  Vital Signs  ................................ ................................ ................................ .................. [ADDRESS_705223] Research Organization  ................................ ................................ ................. 83 
19.1.2.  Interactive Web Response System  ................................ ................................ .............. 83 
19.1.3.  Electronic or Remote Data Capture  ................................ ................................ ............ 83 
19.1.4.  Central Laboratory for Assessments  ................................ ................................ ........... 83 
19.2.  Study Committees  ................................ ................................ ................................ .......83 
19.3.  Changes to Final Study Protocol  ................................ ................................ ................ 83 
19.4.  Ethics Committee Notification of Study Completion or Termination  ........................ 84 
19.5.  Retention of Study Data  ................................ ................................ .............................. 84 
19.6.  Study Report Signatory ................................ ................................ ............................... 84 
20. REFERENCES  ................................ ................................ ................................ ........... 85 
21. INVESTIGATORS SIGNED AGREEMENT OF STUDY PROTOCOL  ................. 90 
APPENDIX  A. PROTOCOL AMENDMENT H ISTORY  ................................ ......................... 91 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 8 Protocol Version 1.1 (specific for Canada)  ................................ ................................ .................... 91 
Protocol Version 2.0 (Global, except Canada)  ................................ ................................ .............. 92 
Protocol Version 2.1 (specific for Canada)  ................................ ................................ .................... [ADDRESS_705224] OF TABLES   
Table 1:  Schedule of Activities for Screening V isit and ITI Period  ................................ ......... 20 
Table 2:  Schedule of Activities for the Tapering and Follow -Up Periods After 
Successful Tolerization  ................................ ................................ ............................... 26 
Table  3: Sampling Schedule for Pharmacokinetic Evaluation (Half -Life)  ............................... 30 
Table 4  Example of a Dose Adjustment Schedule: Negative Inhibitor, Not All 
Success Criteria Met  ................................ ................................ ................................ ...51 
Table 5  Example of a Dose Tapering Schedule: All [ADDRESS_705225] OF FIGURES   
Figure 1:  997HA402 Study Design  ................................ ................................ ............................ 19 
Figure 2  Flow Diagram for Assessment of ITI Outcome  ................................ ......................... 43 
 
 
 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 10 PROTOCOL AMENDMENT S UMMARY OF CHANGES   
 
DOCUMENT HISTORY  
 
Document  Country/countries 
impacted by [CONTACT_540960] 3    All, including Canada  11 July 2019  
Protocol Version 2.1   
(from Version 1.1)  Canada  02 March 2018  
Protocol Version 1.1   
(from Version 1)  Canada  06 July 2017  
Protocol Version 2  All 09 February 2018  
Protocol Version 1  All 19 January 2017  
 
Present amendment to the protocol ( 11-July-2019 ) 
This is a global amendment to the protocol V2.[ADDRESS_705226] been made for Canada and these country -specific changes are outlined in 
Appendix  B. 
PROTOCOL AMENDMENT S UMMARY OF CH ANGES  
Section # and Name  [CONTACT_42407], Section 7.1, and 
Section 16.1.  
 Following texts or similar texts have been added in the 
sections:  
This study will enroll up to 17 subjects , Or 
Approximately, 17 subjects will be treated  The primary reason for this 
amendment  to Protocol 997HA402 
is to reduce the number of subjects 
to be enrolled, to clarify the timing 
for subjects moving from interim ITI 
visits to ITI outcome assessment 
visits, and to clarify sample 
collection sch edules for ADA, and to 
incorporate requests by [CONTACT_540961].  Section 4.2, Section 7.2.2, 
Section [IP_ADDRESS], and Section 
[IP_ADDRESS]  Clarification for the timing for subjects moving from 
interim ITI visits to ITI outcome assessment visits was 
added to the sections and Table 1, Table [ADDRESS_705227] also been created to display history of protocol amendments (Appendix A) and country specific 
requirements (Appendix B).  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 11 1. SPONSOR INFORMATION   
This study is sponsored by [CONTACT_540962]. (Sponsor). Refer to the Study Reference 
Manual  that contains all study contacts for complete contact [CONTACT_3031].  
 
Bioverativ Therapeutics Inc.  
[ADDRESS_705228]  
Waltham, MA [ZIP_CODE]  
[LOCATION_003]  
 Bioverativ Jap an Ltd.  
Nihonbashi 1 -chome Mitsui Building 14F  
4-1 Nihonbashi 1 -chome  
Chuo -ku, Tokyo  
103-0027 Japan  
 
For urgent medical issues in which the study’s Medical Director should be contact[INVESTIGATOR_530], please 
refer to the Study Reference Manual  Official Study Contact [CONTACT_71330].  
Sponsor  may transfer any or all of its study -related responsibilities to contract research 
organization (CRO) and other third parties; however, Sponsor  retains overall accountability for 
these activities.  
VV-CLIN-[ADDRESS_705229]  upper limit of normal  
[LOCATION_003]  [LOCATION_002] of America  
VWF  von Willebrand factor  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 14 3. SYNOPSIS   
Tracking Number:  997HA402  
Protocol Title:  A Non -Controlled, Open -Label, Multicenter, Study of 
Efficacy of rFVIIIFc for Immune Tolerance Induction 
(ITI) in Severe Hemophilia A Subjects with Inhibitors 
Undergoing the First ITI Treatment  
Version Number:  2.0 
Name [CONTACT_71413]:  Antihemophilic factor VIII (recombinant) Fc fusion protein; 
rFVIIIFc; Eloctate®; Elocta® 
Study Indication:  Hemophilia A, ITI  
Phase of Development:  4 
Rationale for the Study:  Hemophilia A ( coagulation factor VIII [FVIII] deficiency) 
is a rare X -linked bleeding disorder and the most common 
type of hemophilia. The most serious treatment 
compli cation for patients with hemophilia A is the 
development of inhibitory immunoglobulin antibodies to 
FVIII. Inhibitors result in rapid clearance of infused FVIII 
and marked reduction, or absence, of efficacy of FVIII 
treatment. FVIII -by[CONTACT_540963] a s activated 
prothrombin complex concentrate  (aPCC [FEIBA ]) or 
recombinant activated factor VII  (rFVIIa [NovoSeven ]) are 
used to treat acute bleeding in patients with high -titer 
inhibitors, but inhibitor eradication remains the goal of 
long-term management.  
Immune tolerance induction (ITI) therapy using frequent 
administration of high doses of FVIII is the only proven 
strategy shown to achieve antigen -specific tolerance 
(Kempton et al., 2014 ; Valentino et al., 2015 ). ITI usually 
attempts to eliminate high -responding FVIII inhibitors 
(≥5 Bethesda Unit [BU] titer). ITI regimens employ 
different doses and dosing frequencies of FVIII, and they 
may or may not involve adjunctive immunomodulatory 
therapy (Franc hini et al., 2011 ; Valentino et al., 2015 ). 
Currently, a range of FVIII products and dosing re gimens 
are used for ITI because there is no clear consensus on an 
optimal regimen (Franchini et al., 2011 ). 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 15 In the International ITI Study, a prospective randomized 
study comparing a high -dose (200  international units 
[IU]/kg/day) and a low -dose (50  IU/kg 3 times per week ) 
FVIII regimen, subjects in the high -dose arm achieved a 
negative titer (median 4.6 months [interquartile range (IQR) 
2.8 to 13.8] vs. 9.2  months [IQR 4.9  to 17.0]; p  = 0.017) and 
a normal recovery (median 6.9  months [IQR 3.5  to 12.0] vs. 
13.6 months [IQR 8.7 to 19.0]; p = 0.001) significantly 
more rapi[INVESTIGATOR_540914] -dose arm. High -dose 
subjects also experienced significantly fewer bleeding 
epi[INVESTIGATOR_540915]-dose subjects, and for this reason, the 
data safety monitoring board recommended study  
termination (Hay & DiMichel e, 2012 ). 
These findings and limited experience in patients with 
hemophilia who have  inhibitors have led to an interest in 
investigating the use of the Extended Half -Life (EHL) 
recombinant coagulation factor VIII Fc fusion protein 
(rFVIIIFc ) in ITI. rFVIIIFc was approved in the United 
States of America ([LOCATION_003]), Canada, and Japan in 2014 with 
the name [CONTACT_541015] 2015 with the name 
[CONTACT_541016].  
Study Objectives and 
Endpoints:  Objectives  
The primary objective of the study is to describe the time to 
tolerization (ITI success , i.e., inhibitor titer <0.6  BU/mL, 
rFVIIIFc incremental recovery [IR] ≥66% of the expected 
IR, and t ½ ≥7 hours ) with rFVIIIFc in subjects within a 
maximum of 12  months (48 weeks) of ITI treatment.   
The secondary objectives are as follows:  
 To describe the outcome of ITI treatment  
 To describe the relapse rate over the 48 -week 
(12-month) period following successful ITI performed 
with rFVIIIFc  
 To describe the intercurrent bleeding during the ITI 
Period and during the 48 -week (12-month) period after 
successful ITI performed with rFVIIIFc  
 To describe the safety and tolerability of rFVIIIFc when 
used for ITI  
 To evaluate the impact of ITI treatment  with rFVIIIFc on 
health economics and adherence  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 16  
The exploratory objectives are as follows:  
  
 
  
 
Endpoints  
The primary endpoint of this study is time to tolerization 
with a maximum of 12 months (48 weeks) of ITI treatment 
offered in the study  (tolerization defined as inhibitor titer 
<0.6 BU/mL, rFVIIIFc incremental recovery [IR] of ≥66% 
of expected, and half -life [t½] of ≥7  hours).  
The s econdary endpoints are as follows : 
 ITI success  
 Confirmed  negative titer s consisting of 2 
consecutive negative inhibitor assessments within 2 
weeks (±3 days) based  on local laboratory results 
<0.6 BU/mL by [CONTACT_471597] -modified Bethesda 
assay ; determination of negative titer based on the 
Bethesda assay is acceptable at sites that have not 
yet adopted the Nijmegen -modified Bethesda assay.  
 IR ≥1.32 IU/dL per IU/kg in 2  consecutive 
assessments represe nting ≥66% of the expected IR 
2 IU/dL per IU/kg. (SmPC ; USPI ) 
 t½ ≥7 hours.  
 Occurrence of relapse (defined as confirmed positive 
inhibitor titer ≥0.6  BU/mL ), abnormal recovery after 
tolerance is achieved, and t ½ <7 hours) during the 
Tapering or Follow -Up Periods  
 Number of bleeding epi[INVESTIGATOR_540916] 48 -week (12-month) period after successful 
ITI performed with rFVIIIFc  
 Adverse events and serious adverse events  
 Number of days away from work or school  
 Number of hospi[INVESTIGATOR_30874]  
 Adherence (defined as percentage of administered doses 
VV-CLIN-0542000 3.0

Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 17 versus planned doses)  
 Consumption of rFVIIIFc (me asured in total rFVIIIFc 
use) 
The e xploratory endpoints are as follows : 
 
  
 
 
  
 
 
The exploratory endpoint  
 will be reported outside the clinical 
study report.  
Study Design:  An open -label, single -arm, interventional, multicenter study 
designed to explore the use of rFVIIIFc for ITI in subjects 
with severe hemophilia A,  who are undergoing ITI 
treatment for the first time.  
The study consists of 1) a 4 -week (1-month) Screening 
Period ; 2) a maximum of a 48 -week (12-month) ITI Period ; 
3) a minimum of a 16 -week (4-month)  Tapering  Period  after 
all criteria for tolerization have been met ; and 4) a 32 -week 
(8-month)  Follow -Up Period . Only subjects who achieve 
ITI success will enter the Tapering and Follow -Up Periods. 
During the Tapering and Follow -Up Periods , the subject’s 
dose will be adjusted to achieve the prophylactic dose.  
Study Location and Number 
of Sites:  Approximately 30 si tes in the [LOCATION_003], Europe, Japan, and 
Canada  
Number of Planned Subjects:  Up to 17 subjects  
Study Population:  This study will be conducted in male subjects of any age 
with severe hemophilia A and high -titer inhibitors 
(historical peak ≥5 BU/mL) , who have bee n previously 
treated with any plasma -derived FVIII or recombinant 
conventional or EHL FVIII and are undergoing ITI 
treatment  for the first time.  
VV-CLIN-0542000 3.0

Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 18 Detailed criteria are described in Section  8. 
Treatment Groups:  This is a single -arm study that will enroll up to 17 subjects  
Duration of Treatment and 
Follow -Up: Study duration for each subject will vary based on time to 
ITI success. The maximum individual subject study duration 
is expected to be approximately 2 years.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 19 
 4. STUDY SCHEMATIC AND SCHEDULE OF ACTI VITIES   
4.1. Study Schematic   
Figure 1: 997HA402  Study Design   
 
Abbreviations: ITI=immune tolerance induction; Max=maximum.  
Only subjects who achieve ITI success within the 48-week (12-month) ITI P eriod  will continue 
into the Tapering and Follow -Up Periods . During the  Tapering and Follow -Up Periods , the 
subject’s dose will be adjusted to achieve the prophylactic dose.  However, if FVIII peak activity  
levels rise above 200  IU/dL after the inhibitors are negative but before all the ITI success criteria 
are met, the dose may be adjusted according to Investigator judgment to maintain  the FVIII peak 
activity  levels between 100 and 200 IU/dL. This dose reduction will not be considered part of the 
Tapering Period , and the subject wil l maintain the schedule of assessments per the ITI Period . 
See Section  11.1 for dosing details.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 20 4.2. Schedules of Activities   
Table 1: Schedule of Activities for Scree ning Visit and ITI Period   
Activities  Screening 
Visit  ITI Period  EOT for Partial Success or Failure1 
Baseline 
Visit  
(within 4 
weeks of 
Screening)  Week 2  
Visit  Interim ITI Visits  ITI Outcome 
Assessment Visit  EOT Visit  Final Safety 
Follow -Up 
Start of 
ITI 
treatment  2 weeks  
(±3 days)  
from start of 
ITI 
treatment  Every 4th week  
(±1 week) 
Starting at ITI 
Week  [ADDRESS_705230] 
negative titer (<0.6 
BU/mL)  is achieved  
OR 48 weeks of ITI 
treatment2 Every 2nd week  
(±3 days)  
Starting at time  of 
first negative  
inhibitor titer until  
ITI success OR 
[ADDRESS_705231] 
Eligibility  X       
Demographics  X       
Medical, Surgical, 
Hemophilia, Inhibitor, 
Bleeding  Epi[INVESTIGATOR_1841] , and 
ITI History  X       
Physical  Examination  X X X X X X  
Height  (cm) X     X  
Weight  (kg) X X X X X X  
Vital  Signs3 X X X X X X  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 21 Activities  Screening 
Visit  ITI Period  EOT for Partial Success or Failure1 
Baseline 
Visit  
(within 4 
weeks of 
Screening)  Week 2  
Visit  Interim ITI Visits  ITI Outcome 
Assessment Visit  EOT Visit  Final Safety 
Follow -Up 
Start of 
ITI 
treatment  2 weeks  
(±3 days)  
from start of 
ITI 
treatment  Every 4th week  
(±1 week) 
Starting at ITI 
Week  [ADDRESS_705232] 
negative titer (<0.6 
BU/mL)  is achieved  
OR 48 weeks of ITI 
treatment2 Every 2nd week  
(±3 days)  
Starting at time  of 
first negative  
inhibitor titer until  
ITI success OR 
48 weeks of  ITI 
treatment   7 to 14 days 
after EOT 
Visit  
Hematology ( Local 
Laboratory )4 X X  X X X  
Blood  Chemistry  
(Local Laboratory )4  X X  X X X  
Urinalysis ( Local 
Laboratory )4,5 X X  X X X  
Viral Analysis (HIV, 
HCV, and HBV)  
(Central Laboratory )6  X       
Blood Sample for 
Analysis of FVIII 
Mutation and HLA 
Allotypi[INVESTIGATOR_007]  (Central 
Laboratory ) (Optional)7  X      
rFVIIIFc  Dosing8  X X X X X  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 22 Activities  Screening 
Visit  ITI Period  EOT for Partial Success or Failure1 
Baseline 
Visit  
(within 4 
weeks of 
Screening)  Week 2  
Visit  Interim ITI Visits  ITI Outcome 
Assessment Visit  EOT Visit  Final Safety 
Follow -Up 
Start of 
ITI 
treatment  2 weeks  
(±3 days)  
from start of 
ITI 
treatment  Every 4th week  
(±1 week) 
Starting at ITI 
Week  [ADDRESS_705233] 
negative titer (<0.6 
BU/mL)  is achieved  
OR 48 weeks of ITI 
treatment2 Every 2nd week  
(±3 days)  
Starting at time  of 
first negative  
inhibitor titer until  
ITI success OR 
48 weeks of  ITI 
treatment   7 to 14 days 
after EOT 
Visit  
Nijmegen -Modified 
Bethesda Inhibitor Assay 
(Both Local and Central 
Laboratories )9  X X X  X X  
Anti-rFVIIIFc Antibody 
(ADA)  (Central 
Laboratories )10  X X  X X X  
Blood Sample for Immune 
Cell Characterization 
(Central Laborator y)11  X  X  X  
FVIII Activity Level  
(Both Local and Central 
Laboratories )12    X X X X  
FVIII Activity for IR 
(Both Local and Central 
Laboratories )13      X   
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 23 Activities  Screening 
Visit  ITI Period  EOT for Partial Success or Failure1 
Baseline 
Visit  
(within 4 
weeks of 
Screening)  Week 2  
Visit  Interim ITI Visits  ITI Outcome 
Assessment Visit  EOT Visit  Final Safety 
Follow -Up 
Start of 
ITI 
treatment  2 weeks  
(±3 days)  
from start of 
ITI 
treatment  Every 4th week  
(±1 week) 
Starting at ITI 
Week  [ADDRESS_705234] 
negative titer (<0.6 
BU/mL)  is achieved  
OR 48 weeks of ITI 
treatment2 Every 2nd week  
(±3 days)  
Starting at time  of 
first negative  
inhibitor titer until  
ITI success OR 
48 weeks of  ITI 
treatment   7 to 14 days 
after EOT 
Visit  
FVIII Activity for t ½ 
Evaluation ( Both Local 
and Central Laborator y)14     X X  
EPD Review, Including 
Review of Bleeding  
Epi[INVESTIGATOR_540917]15   X X X X X  
Nonserious Adverse 
Events   X X X X X X 
Serious Adverse  Events16 X X X X X X X 
Concomitant 
Therapy/Procedures  
Recording  X X X X X X X 
 
Abbreviations: ADA=anti -drug antibody;  BU=Bethesda Unit; EOT=end of treat ment; EPD=electronic patient diary; FVIII=coagulation factor VIII; 
HBV=hepatitis B virus; HCV=hepatitis C virus; HIV=human immunodeficiency virus; HLA=human leukocyte antigen; ICF=informed consent form; 
IR=incremental recovery; ITI=immune tolerance induction; rFVIIIFc=recombinant coagulation factor VIII Fc fusion protein; t½=half -life. 
NOTE: inhibitor titer, FVIII activity level, t½, and IR are all assessed at the local laboratory, with confirmation by [CONTACT_2237].  The Investigators will 
use local laboratory results for decision -making purposes. Hematology, blood chemistry, and urinalysis are assessed only at the local laboratory.   
VV-CLIN-[ADDRESS_705235] , even if it is after the 48 -week (12-month) period, as long as the first test occurred  during the  48-week  
(12-month) period . If the second test confirms t he results of the first test  (<0.6 BU/mL) , the date of ITI outcome  will be the date of the first value, which 
occurred during  the 48 -week  (12-month) period. Fluctuations in i nhibitor levels is common and variability in inhibitor titer is expected. Subjects  will be 
treated on a case -by-case basis.  
2 If, after the initial 3 months  (12 weeks) , there is no downward trend (at least 20% in the inhibitor titer) over a 6 -month (24-week) period that is assessed at 
the Week [ADDRESS_705236] complete the EOT Vi sit as soon as possible.  The second 
(confirmatory) inhibitor test will occur [ADDRESS_705237].  
3 Vital signs include blood pressure, pulse rate, respi[INVESTIGATOR_697], and body temperature. In the event of in -clinic rFVIIIFc injec tions, assessments will be taken 
prior to and 20 (±5) minutes after the end of the rFVIIIFc injection  (if dosing occurs at the visit) . 
4 Blood samples for determination of hematology and b lood chemistry variables and urine dipstick will be collected at Scr eening  Visit , Baseline Visit (before 
the first study treatment administration) , and then every 12 weeks (3 months) from the start of the ITI Period through the time of ITI complete success. If the 
subject completes the ITI Period  in a duration shorter than 12 weeks  (3 months) , these assessments must be completed at the end of the ITI Period . 
5 Dipstick urinalysis, including a protein reading; if the protein reading is positive (≥1+), a full laboratory urinalysis will  be required.  
6 Sample will be collected and tested if there are no HIV testing results available in the medical history 26 weeks (6.5 months) prior to Screening. HCV and 
HBV will only be tested at Screening if there is any indication in the medical record that the subject has prior exposure to plasma -derived coagulation 
factors.  For subjects without prior exposure, the sample will be collected and stored at the central laboratory. If the subject is diagnosed with  HBV or HCV 
during the study , this sample will be analyzed  by [CONTACT_540964].  
7 This assessment is optional, and requires a separate ICF. For subjects whose FVIII mutation and human leukocyte antigen (HLA)  allotype is not documented 
in medical records, samples for analysis of FVIII mutation and HLA allotypi[INVESTIGATOR_540918].   
For Canada  specific requirements : see Appendix B.  
[ADDRESS_705238] not yet 
adopted the Nijmegen -Modified Bethesda Assa y, use of the Bethesda Assay is acceptable.  
10 A whole blood sample will be collected at Baseline OR Screening, every fourth week during interim ITI Visits, during assessment of ITI outcome visits, and 
at EOT. A sample for Anti -rFVIIIFc Antibody (ADA) shou ld be collected at Baseline or Screening, and each consecutive visit, except the Week 2 and 
Safety Follow -Up Visits  when allowed by [CONTACT_540965] . 
11 A whole blood sample will be collected at ITI Day 1 (Baseline Visit, predose) and at Week 8  (Month 2) , as allowable based on subject weight and 
institutional practice regarding blood draw restrictions for pediatric subjects.  
[ADDRESS_705239] a 24 -hour washout. See  Table  3 for details. 
Subjects will be advised to delay administration of their daily dose of rFVIIIFc until after the sample for IR testing is tak en 
14 Subjects will be advised to delay administration of their daily dose of rFVIIIFc until after the sample for t½ is taken. Half -life determination will only be 
performed after IR ≥1.32 IU/dL per IU/kg has been confirmed at [ADDRESS_705240] is an ITI Treatment Failure.  
15 It is recommended that subjects/caregivers enter dosing information immediately after an injection  or within a maximum of 7 days.  
16 Serious adverse even ts are to be monitored and recorded from the time of signing of the ICF.  
 
 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained h erein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 26 Table 2: Schedule of Activities for the Tapering and Follow -Up Periods After Successful Tolerization   
Activities  Tapering Period1 Follow -Up Period1 EOT2 
Tapering Initiation Visit /Telephone 
Call,3 Week  2, 4, 8, 12, and 16  Visits  Week 28 and 40 Visits4 EOT Visit  Final Safety 
Follow -Up 
Starting at ITI success and 
continuing for a minimum of 16 
weeks  
with visits after 2 weeks (±3 days), 
4 weeks (±1  week), and then every 
4th week (±1 week)  Week 28 and 40 visits 
(±2 weeks)1 
following ITI success  Week 48 visit  (±2 
weeks) following ITI 
success  
OR 
upon relapse  7 to 14 days after 
EOT Visit  
Physical  Examination  X X X  
Heig ht (cm)   X  
Weight  (kg) X X X  
Vital  Signs5 X X X  
Hematology ( Local 
Laboratory ) 6, X  X  
Blood  Chemistry ( Local 
Laboratory )6 X  X  
Urinalysis  (Local 
Laboratory )6,7 X  X  
Nijmegen -Modified Bethesda 
Inhibitor Assay  (Both Local 
and Central Laboratories )8 X X X  
Anti-rFVIII Fc Antibody  
(ADA) ( Central Laboratory ) X X X  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 27 Activities  Tapering Period1 Follow -Up Period1 EOT2 
Tapering Initiation Visit /Telephone 
Call,3 Week  2, 4, 8, 12, and 16  Visits  Week 28 and 40 Visits4 EOT Visit  Final Safety 
Follow -Up 
Starting at ITI success and 
continuing for a minimum of 16 
weeks  
with visits after 2 weeks (±3 days), 
4 weeks (±1  week), and then every 
4th week (±1 week)  Week 28 and 40 visits 
(±2 weeks)1 
following ITI success  Week 48 visit  (±2 
weeks) following ITI 
success  
OR 
upon relapse  7 to 14 days after 
EOT Visit  
Blood Sample for Immune 
Cell Characterization 
(Required)  (Central 
Laboratory ) 9 X  X  
rFVIIIFc  Dosing10 X  X X  
FVIII Activity for IR (Both 
Local and Central 
Laboratories )11 X X   
FVIII Activity for t½ 
Evaluation  (Both Local and 
Central Laborato ries)12   X  
FVIII Activity Level  (Both 
Local and Central 
Laboratories )13  X X  
EPD Review,  Including 
Review of Bleeding  Epi[INVESTIGATOR_540919]14 X X X  
Nonserious Adverse  Events  X X X X 
Serious Adverse  Events  X X X X 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 28 Activities  Tapering Period1 Follow -Up Period1 EOT2 
Tapering Initiation Visit /Telephone 
Call,3 Week  2, 4, 8, 12, and 16  Visits  Week 28 and 40 Visits4 EOT Visit  Final Safety 
Follow -Up 
Starting at ITI success and 
continuing for a minimum of 16 
weeks  
with visits after 2 weeks (±3 days), 
4 weeks (±1  week), and then every 
4th week (±1 week)  Week 28 and 40 visits 
(±2 weeks)1 
following ITI success  Week 48 visit  (±2 
weeks) following ITI 
success  
OR 
upon relapse  7 to 14 days after 
EOT Visit  
Concomitant  Therapy/  
Procedures  Recording  X X X X 
Abbreviations: EOT=End of Treatment; EPD=electronic patient diary; ET=early termination; FVIII=coagulation factor VIII; IR=incremental recovery; 
ITI=immune tolerance induction; PK=pharmacokinetic; rFVIIIFc=recombinant coagulation factor VIII Fc fusion protein; t½=half -life. 
NOTE: inhibitor titer, FVIII activity level, t½, and IR are all assess ed at the local laboratory, with confirmation by [CONTACT_2237].  The Investigators will 
use local laboratory results for decision -making purposes.  
Hematology, blo od chemistry, and urinalysis are assessed only at the local laboratory.  
[ADDRESS_705241]’s dose will be adjusted to achieve each subject’s prophylactic dose as determined by [CONTACT_3786]. Minimum Tapering Period  is 16 weeks  (4 months) . Subjects who relapse during the Tapering Period  (i.e., who have confirmation of inhibitor 
develop ment  AND who have confirmed decrease of IR, with or without clinical signs or symptoms ) will proceed immediately to the EO T Visit. Subjects 
will be closely monit ored during the Tapering Period  for potential relapse.   
For Canada specific requirements: see Appendix B.  
2 Timing of the EO T Visit will vary for subjects, as described in Section  7.2.6 . 
3 Once t ½ has  been determined to be ≥[ADDRESS_705242] a Tapering Initiation Visit and/or a Tapering Initiation Telephone Call . If the 
subject has already begun dow ntitration from the 200 IU/kg/day ITI dose  prior to ITI success , the subject will return for the next scheduled visit (the 
Tapering Initiation Visit) 2 weeks from the visit at which t½ was determined to be ≥[ADDRESS_705243] has not already downtitra ted when t½ is 
determined to be ≥[ADDRESS_705244] to begin downtitrating immediately ( Tapering Initiation 
Telephone Call)  Subject’s subsequent visit, which will occur 2 weeks from the visit at whic h t½ was determined to be ≥7 hours, will be the Tapering 
Initiation Visit (see Section  7.2.3 ).  
4 Subjects who do not achieve ITI success within 48 weeks (12 months) will proceed to the ET/EOT Visit. Subjects who develop in hibitors during the 
Tapering or the Follow -Up Period (i.e., w ho relapse) will proceed immediately to the ET/EOT Visit.  
5 Vital signs include blood pressure, pulse rate, respi[INVESTIGATOR_697], and body temperature. Postdose assessments following in -clinic injections will be taken prior 
to and 20 (±5) minutes after the end  of the rFVIIIFc injection  (if dosing occurs at the visit) . 
6 Hematology , blood chemistry, and urine dipstick are to be collected every 12 weeks (3 months) during the Tapering Period . These assessments will also be 
collected at the EOT Visit.  
7 Dipstick urinalysis, including a protein reading; if the protein reading is positive (≥1+), a full laboratory urinalysis will be requi red. 
VV-CLIN-[ADDRESS_705245] ace at each visit in which IR or t ½ is being assessed.  
11 Subjects will be advised to delay administration of the  remainder of the ir daily dose of rFVIIIFc until after the sample for IR is taken. Blood samples will be 
collected for analysis of rFVIIIFc activity for assessment of IR starting at the visit for confirmed negative titers and at all consecutive visits, except for those 
visits where samples for rFVIIIFc t½ determination are drawn, as IR w ill be determined from the same samples. Blood samples will be taken at predose 
(within 30 minutes prior to the start of injection) and postdose (30  ± 5 minutes after the start of injection). If any assessments indicate the possibility of 
relapse at any ti me during the Tapering or Follow -Up Period , the test must be repeated at the following visit to confirm relapse (i.e., IR <66%).  
12 Subjects will be advised to delay administration of the remainder of their  daily dose of rFVIIIFc until after the final pos t-dose sample for t ½ is taken  (i.e., up 
to [ADDRESS_705246] dose) . PK assessments for t ½ determination are to be performed when the subject is in a nonbleeding state and after at least a 24 -hour 
washout (see Table  3).  
13 A sample for FVIII activity can be collected as needed per Investigator discretion. FVIII activity levels can be derived from IR samples;  therefore, a separate 
blood draw for FVIII activity assessment is not required.  
14 It is recommended that subjects/caregivers enter dosing information immediately after an injection or within a maximum of 7 d ays. 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained h erein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 30 Details on sampling for rFVIIIFc are described in Section  13.1.3  and Table  3. 
Table  3: Sampling Schedule for Pharmacokinetic Evaluation (Half -Life)   
Activities  Time in Relation to rFVIIIFc Dosing  
 rFVIIIFc 
Dosing  
50 IU/kg  
Actual 
Potency  First 
Sample 
Postdose  Second 
Sample 
Postdose  Third 
Sample 
Postdose1     Fourth Sample  
Postdose  
Either 30 h 
OR 48 h Sample  
Predose2  
 0 30 min  
(±5 min)  6 h 
(±10 min)  24 h 
(±60 min)  30 h 
(±60 min)  48 h 
(±60 min)  
rFVIIIFc Dosing   X      
PK Assessments2 
3     X  X X X X X 
Abbreviations: h=hours; min=minutes; PK=pharmacokinetic; rFVIIIFc=recombinant coagulation factor VIII Fc 
fusion protein.  
NOTE: t½ assessment will also be performed at EOT for all subjects, unless all 4 postdose PK samples (as above) 
were assessed within 2 weeks of EOT  or, in the case of subjects who fail ITI treatment . 
1 During the IT I Period, the Investigator may forego the fourth PK sample (i.e., the 30 - or 48 -hour sample ), if, i n the 
Investigator’s opi[INVESTIGATOR_1649], the t½ at the third PK sample indicat es that a t½ ≥7 hours cannot be achieved . In this case, 
the Investigator will document the  decision to forego the fourth sample . 
2 Predose sample is to be collected within 30 minutes prior to the start of the rFVIIIFc inj ection.  
 3 Timepoints for PK assessment are measured from the start of the factor injection.   
 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 31 5. INTRODUCTION   
In this study, mal e subjects of all ages with severe hemophilia A and high -titer inhibitors 
(historical peak ≥5 Bethesda Unit [BU]/mL) will receive recombinant coagulation factor VIII Fc 
fusion protein (rFVIIIFc) for first-time immune tolerance induction (ITI) therapy, to e radicate 
and neutralize anti -coagulation factor VIII (FVIII) alloantibodies  (inhibitors) . 
5.1. Overview of Immune Tolerance Induction in the Clinical 
Management of Hemophilia A   
Hemoph ilia A is a rare X -linked bleeding disorder that is caused by a functional deficiency of 
FVIII, a cofactor in the intrinsic coagulation pathway. Hemophilia A is the most common type of 
hemophilia and is categorized based on endogenous FVIII activity levels  as severe 
(<1 international units [IU]/dL), moderate (1 to 5 IU/dL), and mild (>5 to <40 IU/dL) (ISTH 
Factor VIII/IX Scientific Subcommittee (SSC) Working Party on Definitions in Hemophilia, 
2011 ; Srivastava et al., 2012 ; White et al., 2001 ). As there is no available cure for hemophilia A, 
current treatment focuses on replacement therapy with clotting factor con centrates, namely 
plasma -derived FVIII (pdFVIII) or recombinant factor VIII (rFVIII) products.  
The formation of neutralizing anti -FVIII alloantibodies (inhibitors) represents the most serious 
complication related to hemophilia treatment (Kempton et al., 2014 ). Inhibitors are 
immunoglobulin G antibodies formed against sp ecific epi[INVESTIGATOR_540920], which can 
neutralize the coagulation activity of FVIII in plasma and reduce the recovery and half -life (t ½) 
of FVIII. Inhibitors result in rapid clearance of infused FVIII and marked reduction, or absence, 
of efficacy  of FVIII treatment. Approximately 30% of previously untreated patients with severe 
hemophilia A develop inhibitors following exposure to replacement FVIII (Franchini et al., 
2013 ; Gouw et al., 2013 ). The presence of an inhibitor makes it more difficult to control bleeding 
because patients no longer respond to standard doses of replacement FVIII. As a result, patients 
with inhibitors are prone to more bleeds, which can lead to severe joint disease and physical 
disability and, consequently, reduced quality of life (Scalone et al., 2006 ). Patients with 
inhibitor s also have a higher risk of mortality due to bleeding complications (Walsh et al., 2015 ). 
Inhibitors are classified as high -titer or low -titer based on the titer measured by [CONTACT_540966]. Low -titer inhibitors measure <5 BU/mL, are primarily transient (usually spontaneously 
resolve within 6 months but sometimes more slowly), and generally do not reappear upon FVIII 
challenge (Caram et al., 2011 ; Tagariello et al., 2013 ). High -titer inhibitors are defined by a peak 
inhibitor titer ≥5 BU/mL and are usually persistent. While it has been reported that 10% of 
patients with a high -titer inhibitor (≥5 BU/mL) had a transient inhibitor that spont aneously 
resolved within 6  months (Tagariello et al., 2013 ), only 3.4% of patients with a very high -titer 
inhibitor (≥10 BU/mL) had an inhibitor that spontaneously re solved after at least 2 years of 
follow -up (Caram et al., 2011 ), suggesting that a titer of ≥10 BU/mL is a better predictor for a 
persistent inhibitor.  
In patients with low -titer inhibitors, bleeding epi[INVESTIGATOR_540921]. In patients with high -titer 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 32 inhibitors, bleeding epi[INVESTIGATOR_540922] (activated prothrombin 
complex concentrate [aPCC], FEIBA®, factor eight inhibitor by[CONTACT_540967]] or recombinant 
activated factor VII [rFVIIa, NovoSeven®]), which can by[CONTACT_540968], but inhibitor 
eradication remains the goal of long -term management  (see Section  [IP_ADDRESS] ). 
To date, ITI therapy using frequent administration of high doses of FVIII is the only proven 
strategy to achieve antigen -specific tolerance and eradicate FVIII inhibitor s. The goal of ITI is to 
tolerize the immune system to FVIII by [CONTACT_540969] (PK) such that replacement FVIII can be reintroduced at standard doses. A 
successful response to an ITI regimen (i.e., immune tol erance) is based on evaluation of inhibitor 
titer, FVIII recovery, FVIII t ½, and elimination of the anamnestic response to FVIII challenge 
(Kempton et al., 2014 ; Valentino et al., 2015 ). ITI success rates range  from 33% to 88% in 
published studies (Coppola et al., 2009 ; Dimichele, 2009 ; Gringeri, 2007 ; Hay & DiMichele, 
2012 ; Haya et al., 2001 ; Jimenez -Yuste et al., 2016 ; Kreuz, Escuriola Ettingshausen, Vdovin, 
Zozulya, Plyushch, Svirin, Andreeva, Bubanská, et al., 2016 ; Kurth et al., 2011 ; Nakar et al., 
2015 ; Oldenburg et al., 2014 ). Most ITI studies with reported success rates are based on 
retrospective registries or analyses, which may have limitations with the types of data collected. 
The wide variability i n success rates can be attributed to numerous factors, including differences 
in FVIII product types and dosing regimens, patient characteristics, and definitions of success 
and methods for calculating success rates across ITI studies.  
Over the last [ADDRESS_705247] been developed, and all involve frequent, 
often daily, repetitive exposure to FVIII for months or years. ITI usually attempts to eliminate 
high-responding FVIII inhibitors (≥5 BU/mL titer). ITI regimens employ different doses and 
dosing frequencies of FVIII, and they may or may not involve adjunctive immunomodulatory 
therapy (Franchini et al., 2011 ; Valentino et al., 2015 ). Curren tly, a range of FVIII products and 
dosing regimens are used for ITI because there is no clear consensus on an optimal regimen 
(Franchini et al., 2011 ). In the only prospective randomized ITI study ever conducted 
(International ITI Study) comparing a high -dose (200 IU/kg/day) and a low -dose (50 IU/kg 3 
times per week) FVIII regimen, subjects in the high -dose arm achieved a negative titer (median 
4.6 months [interquartile range (IQR) 2.8  to 13.8] vs. 9.2 months [IQR 4.9  to 17.0]; p  = 0.017) 
and a normal recovery (median 6.9 months (IQR 3.5  to 12.0) vs. 13.6 months (IQR  8.7 to 19.0); 
p = 0.001) significantly mo re rapi[INVESTIGATOR_540914] -dose arm. High -dose subjects also 
experienced significantly fewer bleeding epi[INVESTIGATOR_540915] -dose subjects, and for this reason, the 
data safety monitoring board recommended study termination (Hay & DiMichele, 2012 ). 
Although it is recommended that ITI be initiated once an inhibitor titer is <10  BU/mL (Valentino 
et al., 2015 ), a recent study suggests that starting ITI as soon as an inhibitor is diagnosed may 
increase the likelihood of ITI success (Nakar et al., 2015 ). 
Factors that can affect ITI success have been identified in ITI studies. In particular, certain 
patient characteristics , including historical peak inhibitor titer >200 BU/mL, inhibitor titer at ITI 
start ≥10 BU/mL, age at ITI start ≥8 years, time between inhibitor diagnosis and ITI start 
>[ADDRESS_705248] been correlated with decreased ITI success and are 
considered high -risk factors for poor ITI outcome (Gringeri, 2007 ; Hay & DiMichele, 2012 ; 
Kreuz, Escuriola Ettingshausen, Vdovin, Zozulya, Plyushch, Svirin, Andreeva, Bubanská, et al., 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 33 2016 ; Valentino et al., 2015 ). For example, a statistically significant inverse relationship between 
histori cal peak inhibitor titer and ITI success was observed in the International ITI Registry 
(IITR; p  = 0.004) and North American ITI Registry (NAITR; p  = 0.001) (DiMichele et al., 2002 ; 
Mariani et al., 1994 ). Immune tolerance was achieved in 82% of patients whose historical peak 
inhibitor titer was <50  BU/mL, compared with 52% and 21% of patient s whose historical peak 
inhibitor titer was >200 BU/mL in the IITR and NAITR, respectively (Kroner, 1999 ). In 
addition, a statistically significant association between inhibitor titer at ITI start (≤10  BU/mL vs. 
>10 BU/mL) and ITI outcome (p  = 0.0068) was observed in the Observational ITI Study (Kreuz, 
Escuriola Ettingshausen, Vdovin, Zozulya, Plyushch, Svirin, Andreeva, Bubanská, et al., 2016 ), 
and an inhibitor titer <[ADDRESS_705249] predictor of ITI success in the 
IITR (80% vs. 60%; p  < 0.002), NAITR (83% vs 40%; p  = 0.001), and a retrospective survey of 
81 patients in the [LOCATION_002] (100% vs 7 8%; p  < 0.0001) (Damiano et al., 2000 ; DiMichele et 
al., 2002 ; Mariani et al., 1994 ). 
Reported success rates can reflect different methods for calculation. For example, in the 
International ITI Study, a prospective study  conducted in patients without high -risk factors, the 
success rate was 40% (46/115) for all subjects, 47% (37/78) for subj ects who completed or 
withdrew from the study, and 70% (46/66) when subjects who were ongoing or withdrawn were 
excluded (Hay & DiMichele, 2012 ). 
Additional prospective studies are needed to better understand ITI success rates. To date, there 
are few anecdotal case reports that de scribe the use of rFVIIIFc for the treatment of ITI. This 
prospective study is aimed at assessing the outcomes of ITI therapy with the use of rFVIIIFc.  
5.2. Profile of Previous Experience With rFVIIIFc for Immune Tolerance 
Induction   
5.2.1.  Previous Nonclinical and Clinical Experience With rFVIIIFc for Immune 
Tolerance Induction   
rFVIIIFc is produced in a human cell l ine (HEK293) as a recombinant B -domain deleted factor 
VIII fused to the Fc domain of human IgG. HEK -produced proteins have the same 
post-translational modifications as native human proteins, in contrast to proteins produced in cell 
lines from other species , such as hamsters (e.g., Chinese hamster ovary [CHO] cells). In such 
proteins, nonhuman glycans (such as N -glycolylneuraminic acid [NGNA]) resulting from the 
post-translational modifications can be potentially immunogenic. NGNA is not found in 
rFVIIIFc.  
Until recently, all rFVIII products were produced in hamster cells (baby [CONTACT_540970]). Today, in addition to rFVIIIFc, there is only one recently approved rFVIII product 
produced in a human cell line available on the market (Lissitchkov et al., 2015 ). 
5.2.2.  Nonclinical Experience   
Nonclinical studies have shown that fusion proteins containing IgG or the Fc domain can induce 
tolerance to the A2 and C2 domains of the FVIII molecule, which are the most frequent epi[INVESTIGATOR_540923]. In one study, FVIII -deficient mice were tr eated with B cells expressing 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 34 full-length IgG fused to either the A2 or C2 domain (Lei et al., 200 5). Inhibitor titers were 
significantly reduced in animals treated with a combination of B cells expressing the A2 -IgG and 
C2-IgG fusion proteins compared with control animals. In another study, a fusion protein 
comprising Fc and either the A2 or C2 domain was transplacentally delivered to the progeny of 
FVIII -deficient (HemA) pregnant mice (Gupta et al., 2015 ). The combination of A2Fc and C2Fc 
fusion proteins led to a significant reduction in inhibitor titers in the offspring of treated mother 
mice compared with the offspring of control mother mice. In both studies, the tolerogenic effect 
of the fusion proteins  involved the induction of regulatory T cells.  
In line with the above findings that suggest a role of the Fc domain in tolerance, nonclinical data 
suggest that rFVIIIFc as such can induce tolerance to FVIII. In a nonclinical study, 
FVIII -deficient mice th at were pretreated with rFVIIIFc had reduced total anti -FVIII IgG 
antibody and FVIII inhibitor production upon challenge with a high dose of rFVIIIFc 
(Krishnamoorthy et al., 2016 ). Toler ance induced by [CONTACT_540971] a higher 
percentage of regulatory T cells, a lower percentage of pro -inflammatory T cells in the spleen, 
and upregulation of cytokines associated with attenuation of the immune response.  
5.2.3.  Clinical Experience   
In the clinical setting, there are published case reports of patients who have received rFVIIIFc for 
ITI. Malec and coworkers described 3 patients with severe hemophilia A (age s at initiation of ITI 
were  18 months, 7.5 years, and 10 years) who were started on ITI with rFVIIIFc after detection 
of a high -titer inhibitor. ITI was initiated at a dose of 100 to 200 IU/kg rFVIIIFc with a dosing 
interval of every other day to 3 times per we ek. ITI led to a negative inhibitor in all 3  children 
within 4 to 12 weeks  (Malec et al., 2015 ) , which is shorter than the median time to negative 
inhibitor reported for other FVIII products (Hay, DiMichele, et al., 2012 ; Kreuz, Escuriola 
Ettingshausen, Vdovin, Zozulya, Plyushch, Svirin, Andreeva, Bubanska, et al., 2016 ). Malec and 
coworkers reported the time to tolerization in the se 3 patients being 17  weeks, 18 weeks, and 17 
months , respectively  (Carcao et al., 2017 ; Malec et al., 2016 ). Groomes and coworkers reported a 
15-month -old patient who started ITI on conventional rFVIII products. As the inhibitor titer 
continued to increase, he was switched to rFVIIIFc 50  IU/kg 3 times per week. The inhibit or titer 
had significantly decreased to 0.7  BU/mL after 10 months of ITI at the time of publication 
(Groomes et al., 2016 ). 
5.3. Study Rationale   
Hemophilia management has advanced rapi[INVESTIGATOR_540924]. Formation of inhibitors still 
remains the main complication of treatment of hemophilia. ITI is the standard of care for 
treatment of inhibitor development for patients with hemophilia A; how ever, there remains an 
unmet need for a standard dose and a specific product to treat these inhibitors. A range of FVIII 
products and dosing regimens have been studied in a number of generally small retrospective 
registries and 1 prospective study . ITI suc cess rates from these studies range from 33% to 88%, 
due in part to the widely varying definitions of success, FVIII product types used, dose regimens, 
and study populations. The International ITI Study was the only prospective study performed to 
date (Hay & DiMichele, 2012 ). This  study evaluated high -dose ( 200 IU/kg/day) and low -dose 
(50 IU/kg 3 times per week) ITI regimens in subjects without risk factors associated with poor 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 35 ITI outcomes. Of the 57 subjects who received high -dose ITI with FVIII, 22  (39%) achieved 
complete succes s. Based on the results of this study and several registries, Valentino (Valentino 
et al., 2015 ) published recommendations on ITI treatment. However, there is no clear consensus 
on an optimal regimen, making additional prospective studies necessary.  
Furthermore, rFVIIIFc offers a potential advantage over other replacement FVIII product s for 
treating patients with hemophilia A and inhibitors. Based on reports from animal studies, 
Fc-containing fusion proteins have immunomodulatory properties, which may be attributable to 
the ability to upregulate regulatory T cells via epi[INVESTIGATOR_540925] i n the Fc fragment (De Groot et 
al., 2008 ) and consequently promote tolerance over immune responses that induce 
immunogenicity. These and other nonclinical data (Krishnamoorthy et al., 2016 ) indicate a 
mechanistic basis for the use of rFVIIIFc for ITI, and promising clinical results from published 
reports (Groomes et al., 2016 ; Malec et al., 2015 ) provide initial evidence that rFVIIIFc can 
induce tolerance.  
5.4. Rationale for Dosing Regimen   
The proposed dose of rFVIIIFc for ITI (200 IU/kg/day [± 8 hours]) is aligned with current ITI 
guidelines (Valentino et al., 2015 ). Since cl earance is expected to be very rapid in the presence 
of inhibitors irrespective of the type of FVIII product, the high dose of 200 IU/kg/day evaluated 
in the International ITI Study will be used in the present study to achieve faster tolerization with 
fewe r bleeding epi[INVESTIGATOR_1841]. This dosing regimen is also supported by [CONTACT_109972] a prospective 
clinical study that compared subjects treated with FVIII for ITI at a high dose (200  IU/kg/day) 
and a low dose (50 IU/kg 3 times per week). Results from this study (Hay & DiMichele, 2012 ) 
demonstrated that the times to achieve negative inhibitor titer, normal FVIII recovery, and FVIII 
tolerance were shorter in subjects treated with the high dose of FVIII compared with subjects 
treated with the low dose. Furthermore, subjects treated with the high dose of FVIII for ITI had a 
lower rate of intercurrent bleeding and fewer hospi[INVESTIGATOR_540926] . Anecdotal unpublished reports of cases treated in the United 
States of America ([LOCATION_003]) and Canad a with 200  IU/kg/day also exist.  
Furthermore, repeated doses of up to 1000  IU/kg evaluated in the nonclinical animal studies have 
shown no dose -limiting toxicities.  
Sustained high FVIII activity levels in plasma (>150 to 200 IU/dL ) may increase the risk of 
thrombotic events , although this risk is thought to be low. Therefore, FVIII activity levels in 
plasma will be monitored to provide a basis for dose adjustment of rFVIIIFc when needed. 
During the Tapering and Follow -Up Periods , the subject’s dose will be adjusted to achieve a 
prophylactic dose (see Section  11.1).  
 
  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 36 6. STUDY OBJECTIVES AND  ENDPOINTS   
6.1. Primary Objective and Endpoint   
The primary objective of this study is to describe the time to tolerization (i.e., ITI success) with 
rFVIIIFc in subjects within a maximum of  48 weeks (12 months)  of ITI treatment.  
The primary endpoint of this study is time to tolerization with a maximum of 48 weeks ( 12 
months ) of ITI treatment offered in the study  (tolerization defined as inhibitor titer <0.6  BU/mL, 
rFVIIIFc incremental recovery [IR] ≥66% of the expected IR, and t ½ ≥7 hours).  
6.2. Secondary Objectives and Endpoints   
The seconda ry objectives are as follows:  
 To describe the outcome of ITI treatment  
 To describe the relapse rate over the 48 -week (12-month) period following successful 
ITI performed with rFVIIIFc  
 To describe the intercurrent bleeding during the ITI Period and during t he 48 -week 
(12-month) period after successful ITI performed with rFVIIIFc  
 To describe the safety and tolerability of rFVIIIFc when used for ITI  
 To evaluate the impact of ITI treatment with rFVIIIFc on health economics and 
adherence  
The secondary endpoints are as follows:  
 ITI success  
 Confirmed n egative titer s consisting of 2 consecutive negative inhibitor 
assessments within 2 weeks (±3 days)  based on local laboratory results 
<0.6 BU/mL by [CONTACT_471597] -modified Bethesda assay ; determination of 
negative titer  based on the Bethesda assay is acceptable at sites that have not yet 
adopted the Nijmegen -modified Bethesda assay  
 IR ≥1.3 2 IU/dL per IU/kg in 2 consecutive assessments representing ≥66% of the 
expected IR 2 IU/dL per IU/kg (SmPC ; USPI ) 
 t½ ≥7 hours  
 Occurre nce of relapse (defined as confirmed positive inhibitor titer ≥0.6 BU/mL ), 
abnormal recovery after tolerance is achieved , and t ½ <7 hours ) during the Tapering 
or Follow -Up Periods   
 Number of bleeding epi[INVESTIGATOR_540927] 48 -week (12-
month) period after successful ITI performed  with rFVIIIFc  
 Adverse events  (AEs)  and serious adverse events  (SAEs)  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 37  Number of days away from work or school  
 Number of hospi[INVESTIGATOR_30874]  
 Adherence (defined as percentage of administered doses versus planned doses)  
 Consumption of rFVIIIFc (measured in  total rFVIIIFc use)  
6.3. Exploratory Objectives and Endpoints   
 
VV-CLIN-[ADDRESS_705250] study duration is expected to be approximately 2 years (see Figure 1 for a 
schematic of the study design).  
7.2. Overall Study Duration and Follow -Up  
The study period will consist of 4 periods: 1) a 4 -week (1-month) Screening Period ; 2) a 
maximum of a 48-week (12-month) ITI Period ; 3) a minimum of a 16 -week (4-month) Tapering 
Period  after all criteria for tolerization have been met; and 4) a 32 -week (8-month) Follow -Up 
Period. The length and the dosing schedule s during the Tapering Period  are left to th e discretion 
of the treating physician. Only subjects who achieve ITI success will enter the Tapering and 
Follow -Up Periods . During the Tapering and Follow -Up Periods , the subject’s dose will be 
adjusted with the aim of tapering the dose to reach the proph ylactic dosing regimen within at 
least 12 weeks (3  months) ( see Table  5). 
7.2.1.  Screening   
Subjects will undergo full evaluation to determine their eligibility to participate in the study , 
after the subject  or the subject’s legally authorized representative (e.g.,  parent or legal guardian), 
as applicable, in accordance with local practice and regulations, has signed  the informed consent 
form (ICF)  (and assent, if applicable) . Pediatric subjects  who have the capacity should provide 
their assent to participate in the study.  
Subject eligibility for the study will be determined within 4 weeks (1 month) prior to study entry, 
with the exception of informed consent, which may occur earlier. Subjects m ay be given a 
screening w indow extension of up to 2 weeks if unable to enroll within the 4 -week (1 month) 
Screening Period. Screening laboratory results are valid for up to 6 weeks. Screen failures will be 
allowed to re -screen on a case -by-case basis and will require approval of the Sponsor  Medical 
Monitor. Subjects weighing <[ADDRESS_705251] document the rationale.  
Subjects who meet all entry criteria will be enrolled and begin treatment at the Baseline Visit  
(see Table 1). A subject will be  considered enrolled when the Investigator determines that the 
subject is eligible, and the subject is enro lled in the Interactive  Response System ( IXRS ). Subject 
enrollment in IXRS must occur prior to dispensation of study treatment.  
VV-CLIN-[ADDRESS_705252] dose of rFVIIIFc ITI will be administered at the Baseline Visit, and treatment will 
continue  until ITI success is declared or for a maximum of 48 weeks  (12 months) . The ITI 
regimen consists of rFVIIIFc 200 IU/kg/day ( ±8 hours) , which may be given as once -daily 
injections or divided into several injections per day at the discretion of the Investig ator.  
Subjects will visit the clinic 2 and 4 weeks after enrollment and then every fourth week until 
48 weeks (12 months) or until a negative inhibitor (<0.6  BU/mL) has been obtained. After the 
negative inhibitor result s, visits will be scheduled every other week until ITI success or failure is 
declared.  
The Investigator’s  assessment of ITI outcome  will b e based on results from the local laboratory . 
If the local laboratory results are inconclusive , the Investigator may use the central laboratory 
results to determine ITI outcome . During the ITI Period , subjects will undergo procedures and 
assessments at designated visits per Table 1. Samples for inhibitor testing and assessment of 
FVIII activity levels will be analyzed at the local laboratory and at the central laboratory . 
Investigator treatment and assessment of inhibitor status will be based on results from the local 
laboratory. Negative i nhibitor testing results must be confirmed (i.e., 2 consistent results at 2 
consecutive assessments ). See Section  [IP_ADDRESS]  for specific definitions of ITI outcomes.  
The assessment of ITI outcome is illustrated in Figure 2. After the subject has demonstrated a 
negative inhibitor (<0.6 BU/mL) at 2 consecutive assessments within 2 weeks (±3 days) per the 
schedule listed in  Table 1, an evaluation of rFVIIIFc IR will be performed at the next scheduled 
visit (the interpretation of the IR result will be performed after the negative inhibitor titer is 
confirmed, but the sample for IR is drawn at the visit for the confirmatory negative inhibitor 
titer). After IR ≥1.32 IU/dL per IU/kg (≥66% of the expected IR) has been obtained at 
2 consecutive assessments within 2 weeks (±3 days), together with a sustained negative in hibitor 
titer (<0.6  BU/mL), PK assessments to determine rFVIIIFc t ½ will be performed at the 
subsequent visits until t ½ ≥7 hours is attained. If t ½ <7 hours is attained, subjects need to return to 
clinic within 2  weeks (±3 days) to complete another t ½ assessment until ITI success or 48 weeks 
(12 months).  
Subjects are required to have at least a 24 -hour washout prior to the IR and the PK assessment 
for t ½. The dose for IR and t ½ is 50 IU/kg of rFVIIIFc based on actual potency. Investigators will 
advise subj ects to delay any dose of rFVIIIFc until after scheduled inhibitor assessments. 
Investigators will also advise subjects to delay the remainder of their daily dose of rFVIIIFc until 
after IR and t ½ assessments have been made.  
Only subjects who achieve confirmed ITI success within 48 weeks (12 months) will continue 
into the Tapering and Follow -Up Periods. Throughout the study, FVIII activity levels above 
200 IU/dL (based on local laboratory values) should be avoided. However, if FVIII activity  
levels ris e above 200  IU/dL after the inhibitors are negative but before all of the ITI success 
criteria are met, the dose may be adjusted according to Investigator judgment to maintain  the 
FVIII activity  levels between 100 and 200 IU/dL. This dose reduction will no t be considered part 
of the Tapering Period , and the subject will maintain the schedule of assessments per the ITI 
Period.  See Section  11.[ADDRESS_705253] and/or his caregiver in a st udy-specific 
electronic patient diary  (EPD) . EPD  data will be reviewed by [CONTACT_540972].  
[IP_ADDRESS].  Use of By[CONTACT_540973]’s signing the ICF and the beginning of ITI treatment, 
treatment with by[CONTACT_71363] (aPCC [FEIBA] or rFVIIa [NovoSeven]) is permitted.  
During ITI treatment, subjects may also receive by[CONTACT_540974] f or control of active 
bleeding at the discretion of the Investigator and within labeled dosing recommendations for the 
specific by[CONTACT_71360].  
The Investigator may also prescribe by[CONTACT_540975] a high clinical suspi[INVESTIGATOR_540928]. When possible, bleeding should be confirmed via physical 
examination and/or imaging prior to administration of a by[CONTACT_71360];  Confirmation of 
bleeding should not cause any unnecessary delay in the start of treatment, as judged by [CONTACT_3786].  
In the event of an emergency, prior consultation with the Investigator is not required before 
administration of a by[CONTACT_71360]; ho wever, the Investigator must be notified of such use.  
The use of by[CONTACT_540976].  
In subjects with high -titer inhibitors, bleeding ma y be treated with by[CONTACT_71363], which can 
by[CONTACT_540968]. In subjects with low -titer inhibitors, bleeding events may be controlled 
with increased doses of replacement FVIII to overwhelm the inhibitor by [CONTACT_71362].  
During the study, the In vestigator will determine if increased doses of replacement FVIII or use 
of by[CONTACT_71365].   
It is recommended that Investigators discontinue the use of by[CONTACT_71368] <0.6 BU/mL (negative titer, or values con sidered negative per local laboratory reference) 
or once rFVIIIFc provides sufficient hemostatic control, as judged by [CONTACT_737].  
The prophylactic use of by[CONTACT_540977] ; however, the  Investigator must inform the Sponsor  Medical Monitor and document 
the rationale for such use.  
Throughout the ITI Period, rFVIIIFc administration, by[CONTACT_540978], and any 
bleeding epi[INVESTIGATOR_540929]/or his caregiv er in a study -specific EPD.  
EPD data will be reviewed by [CONTACT_540979].   
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 41 [IP_ADDRESS].  ITI Outcome   
ITI outcome will be asses sed on an ongoing basis. Subjects may achieve 1 of 4 outcomes: 
treatment failure, early withdrawal (outcome not determinable) during the ITI Period , partial 
success, or  ITI success.  
Early withdrawal (Outcome not determinable)  
 Unable to determine outcome du e to withdrawal during the ITI Period  
Treatment failure  
Treatment failure is defined as fulfilling one of the following criteria:  
 No downward trend of at least 20% in the inhibitor titer in a 6 -month (24-week) 
period after the initial 3 months (12 weeks) during the ITI Period  (assessed at the 
Week 36 [Month 9] Visit) .  
 Presence of a sustained positive inhibitor (≥0.6 BU/mL) after 48 weeks (12 months) 
of ITI  treatment . 
 Negative inhibitor titer without achieving either of the 2 PK parameters of ITI success  
after 48 weeks (12 months) of ITI treatment :  
 IR ≥1.3 2 IU/dL per IU/kg OR  
 t½ ≥[ADDRESS_705254] failed ITI will then proceed to the End of Treatment 
(EOT ) Visit.  
Partial success  
Partial success is defined as achieving negative inhibitor titer and one of the PK parameters of 
ITI success: IR ≥1.3 2 IU/dL per IU/kg OR t ½ ≥[ADDRESS_705255] completed the 
maximum period of 48 weeks (12 months) of ITI treatment but do not fulfill the criteria for ITI 
success or treatment failure   
Subjects who have been determined to have achi eved only partial success will then proceed to 
EOT Visit . 
ITI success  
ITI success is defined as achieving all 3 of the following criter ia based on local laboratory 
results : 
 Confirmed n egative inhibitor titer (<0.6 BU/mL by [CONTACT_471597] -modified Bethesda 
assay) based on 2 consecutive negative inhibitor assessments  within 2  weeks 
(±3 days) ; determination of negative titer based on the Bethe sda assay is acceptable at 
sites that have not yet adopted the Nijmegen -modified Bethesda assay  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 42  IR ≥1.3 2 IU/dL per IU/kg, representing ≥66% of the expected IR 2 IU/dL per IU/kg 
(SmPC ; USPI ), at 2 consecutive assessments performe d within 2 to 4 weeks  
 t½ ≥7 hours  
 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 43 Figure 2 Flow Diagram for Assessment of ITI Outcome   
 
Abbreviations: BU=Bethesda unit; IR=incremental recov ery; ITI=immune tolerance induction; t ½=half -life. 
After c onfirmed negative inhibitor tit er (<0.6 BU/mL), it is stated ‘Perform these assessments (i.e. inhibitor titer every 2 weeks, and IR every 2 weeks) for the 
remainder of the ITI Period after negative titer (< 0.6 B U/mL) is confirmed’. Although this means that the sample for IR is drawn at the vi sit for the confirmatory 
negative inhibitor titer, however,  the inte rpretation of the IR result will  be performed after  the negative inhibitor titer is  confirmed.
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
 
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consen t of 
Bioverativ Therapeutics Inc.  
Page 44 7.2.3.  Downtitration (Dose Adjustment) Between ITI Treatment and the Tapering 
Period   
If FVIII activity  levels rise above 200  IU/dL, after the inhibitors are negative but before all of the 
ITI success criteria are met, the dose will be adjusted according to Investigator judgment  to 
maintain the FVIII activity  levels between 100 and 200 IU/dL. This dose adjustment will not be 
considered part of the Tapering Period, and the subject will maintain the schedule of assessments 
per the ITI Period.  
Once t½ has been determined to be ≥[ADDRESS_705256] a Tapering Initiation 
Visit and/or a Tapering Initiation Telephone Call. If the subject has already begun downtitration 
from the 200 IU/kg/day ITI dose, the subject will return for the next sch eduled visit (the 
Tapering Initiation Visit) 2 weeks from the visit at which t½ was determined to be ≥[ADDRESS_705257] has not already downtitrated when t½ is determined to be ≥[ADDRESS_705258] to begin downtitrating immediately (Tapering 
Initiation Telephone Call). Subject’s subsequent visit, which will occur 2 weeks from the visit at 
which t½ was determined to be ≥[ADDRESS_705259] met the criteria for ITI success will enter the Tapering Period . Further details 
about the recommended dosing regimen for tapering are described in Section  11. Subjects with 
bleeding  epi[INVESTIGATOR_540930] .  
During the Tapering Period, tre atment with by[CONTACT_540980]  (see Section  [IP_ADDRESS] ). Testing for recurrence of 
inhibitors will be performed throughout the Tapering and Follow -Up Periods .  
Subjects will visit the clinic [ADDRESS_705260] visit in the Tapering Per iod and then 
every fourth week for a minimum of 16 weeks  (4 months) . The duration of the Tapering Period  
may be modified by [CONTACT_540981]’s approval based on the 
subject’s clinical response. If the Tapering Period  exceed s 16 weeks  (4 months) , unscheduled 
visits will be performed every 4 weeks (1 month) or per the Investigator’s judgment.  
During the Tapering Period , subjects will undergo procedures and assessments at designated 
visits per the schedule of events (see Table 2). At each visit, samples for inhibitor titer and IR 
assessments will be drawn and sent to the local and central laboratories to monitor for rel apse.  
If the subject experiences bleed ing during the Tapering Period , the treatment of the bleed ing will 
be left to the discretion of the Investigator. During the Tapering Period , treatment with by[CONTACT_540982] (see 
Section  [IP_ADDRESS] ). 
Throughout the Tapering Period, rFVIIIFc administration, by[CONTACT_540978], and 
any bleeding epi[INVESTIGATOR_540929]/or his caregiver in the EPD. The EPD 
data will be reviewed by [CONTACT_540983].  
VV-CLIN-[ADDRESS_705261] experiences bleeding epi[INVESTIGATOR_540931], 
further investigation for relapse may be warranted.  
Relapse is defined as the occurrence of the following (with or without clinical signs or 
symptoms) after complete ITI success, based on the Internatio nal ITI criteria (Hay & DiMi chele, 
2012 ): 
 A positive inhibitor (≥0.6 BU/mL using the Nijmegen assay) on 2 consecutive 
assessments performed within 2 to 4 weeks; determination of positive titer based on 
the Bethesda assay is acceptable at sites that have not yet adopted the 
Nijmegen -modified Bethesda assay.  
AND  
 An IR <1.3 2 IU/dL per IU/kg (representing <66% of the expected IR) on [ADDRESS_705262] 
with confirmed relapse (i.e., confirmation of both of the above criteria in 2 consecutive 
assessments) must complete the EO T Visit.  At EOT, t½ will be assesse d and recorded.  
7.2.5.  Follow -Up  
After completion of the Tapering Period , subjects will enter the Follow -Up Period , during which 
subjects will be treated prophylactically with the rFVI IIFc dose and interval prescribed by [CONTACT_3786], according to the label and clinical response of the subject, for 32 weeks  (8 months) . 
To avoid bleed ing epi[INVESTIGATOR_1865] s and a relapse of the inhibitor s, FVIII activity  levels should be kept 
≥1 IU/dL.  
If the subject experiences a bleed ing epi[INVESTIGATOR_540932] -Up Period , the treatment of the 
bleed will be left to the discretion of the Investigator. Treatment with by[CONTACT_540984]. Subjects with bleeding 
epi[INVESTIGATOR_540933] -Up Period will be tested for recurrence of inhibitors  (see 
Section  [IP_ADDRESS] ). 
During the Follow -Up Peri od, the subject will visit the clinic every 12 weeks (3 months) and  
undergo procedures and assessments as per the schedule of activities ( see Table 2). At each visit, 
samples for inhibitor titer and IR assessments will be drawn to monitor for relapse. A subject 
with confirmed relapse criteria will complete the EOT Visit as soon as possible.  
7.2.6.  End of Treatment /End of Study   
At the EOT Visit, PK assessments to determine rFVIIIFc t ½ will be performed. t½ determination 
at EOT Visit does not need to be performed if the full [ADDRESS_705263] is an ITI 
Treatment Failure (see Section  [IP_ADDRESS] ). Throughout the Follow -Up Period , rFVIIIFc 
VV-CLIN-[ADDRESS_705264] and/or his caregiver in 
the EPD . The EPD  data will be reviewed by [CONTACT_540985].  
7.2.7.  Final Safety Follow -Up  
A Final Safety Follow -Up Visit or Follow -Up T elephone Call will take place within [ADDRESS_705265] the regular visit schedule and assessments.  
7.4. Study Stoppi[INVESTIGATOR_540934], after informing the Investigator(s). Sponsor  will 
notify Investigator (s) if the study is placed on hold, completed, or terminated.  
Sponsor  may also stop the study for futility and not meeting the enrollment targets.  
7.5. End of Study   
The end of study is defined as last subject, last visit for final collection of data.  
VV-CLIN-[ADDRESS_705266] meet the following eligibility criteria 
at the time of enrollment : 
1. Ability of the subject or his legally authorized representative (e.g., parent or legal 
guardian) to understand the purpose and risks of the study and provide signed and dated 
inform ed consent and authorization to use protected health information in accordance 
with national and local subject privacy regulations  
2. Male subjects of any age diagnosed with severe hemophilia A (as confirmed from the 
medical record)  
3. Currently diagnosed with high-titer inhibitors (historical peak ≥5 BU/mL, according to 
medical records)  
4. Previously treated with any pd-FVIII or recombinant conventional or Extended Half -Life 
FVIII  
5. Canada specific requirements: See Appendix B.  
8.2. Exclusion Criteria   
Candidates will be excluded from study entry if any of the following exclusion criteria exist at 
the time of enrollment:  
1. Other coagulation disorder(s) in addition to hemophilia A  
2. Previous ITI  
3. History of hypersensitivity or anaphylaxis associate d with any FVIII administration  
4. Planned major surgery scheduled during the study unless deferred until after study 
completion (minor surgery such as tooth extraction or insertion/replacement of central 
venous access device is allowed)  
5. Abnormal renal function (serum creatinine > 1.5 mg/dL  or 2× upper limit of normal 
(ULN ) for subject age based on local laboratory range ) as assessed by [CONTACT_12117]  
6. Serum alanine aminotransferase or aspartate aminotransfer ase >5 × ULN as assessed by 
[CONTACT_12117]  
7. Serum total bilirubin >3 × ULN as assessed by [CONTACT_12117]  
8.  Current enrollment or a plan to enroll in any interventional clinical study in which an 
investigational treatment or approved therapy , other than r FVIIIFc, for investigational use 
is administered within 30 days (or 5 half -lives of the agent, whichever is long er) prior to 
the Baseline Visit  
9. Inability to  comply with study requirements  
VV-CLIN-[ADDRESS_705267]’s ability to comply with the 
protocol requirements or make the subject not appropriate for inclusion to the study and 
treatment with Elocta®/Eloctate® (rFVIIIFc)  
11. Other unspecified  reasons that, in the opi[INVESTIGATOR_12182] , make the 
subject unsuitabl e for enrollment  
12. Unwillingness or inability to comply with the requirements of the protocol, including the 
presence of any condition (physical, mental, or social) that prevents the subject from 
participating in visits as scheduled  or entering required information into the EPD in a 
timely manner  
13. Concurrent systemic treatment with immunosuppressive drugs within 12 weeks 
(3 months) prior to Screening. Exceptions to this include ribavirin for treatment of 
hepatitis C virus (HCV), and/or systemic steroids (a total of 2 courses of pulse treatments 
lasting no more than 7  days within 12 weeks [3 months ] prior to  Day 1) and/or inhaled 
steroids 
14. High risk of cardiovascular, cerebrovascular, or other thromboembolic events, as judged 
by [CONTACT_540986] 26 weeks (6.5 months) prior to Screening. 
If not available, a new test will be drawn at the Screening Visit.  
15. Cluster of differentiation 4 (CD4) lymphocytes <200 mm3 at Screening, if known as 
human immunodeficiency virus (HIV) antibody positive based on medical history or HIV 
testing  
16. Viral load of >400 copi[INVESTIGATOR_014]/mL at Screening, if known as HIV a ntibody positive based on 
medical history  
VV-CLIN-[ADDRESS_705268] not been excluded based on the 
exclusion criteria in Section  8.2. 
9.1. Screening, Enrollment   
Subjects or their legally authorized representative (e.g., parent or legal guardian), where 
applicable, must provide informed consent before any Screening tests or assessments are 
performed. Participating study sites are required to register all screened candidates in this  study 
in the IXRS. If a subject is exclud ed from the study, the reasons for exclusion will be 
documented in the subject’s documents.  
9.2. Registration of Subjects   
At the Screening Visit, IXRS  will be used to assign each subj ect a unique [ADDRESS_705269] 
identification number (see Section  19.1.2 ). No subject may begin treatment prior to enrollment. 
Subject identification numbers that have been assigned will not be reassigned to another subject, 
even if the subject does not receive treatment. If a subject is rescreened, the subject may use his 
original number.  
See the Study Reference Manual  for details on registration.  
VV-CLIN-[ADDRESS_705270] be withdrawn from the treatment and the study for any one of the following 
reasons:  
 The sub ject withdraws consent or the parent or legally authorized representative (e.g., 
parent or legal guardian) withdraws consent on behalf of the subject.  
 The subject is unwilling or unable to comply with the protocol.  
 The subject enrolls into another interventional clinical study in which an 
investigational treatment or approved therapy for investigational use is administered.  
 ITI treatment is interrupted for >2 weeks.  
 Emergent or elective surgery. Minor surgery such as tooth extraction or 
insertion/re placement of central venous access device is not a criterion for 
withdrawal.  
 The subject received concomitant immunomodulation.  
 The subject uses FVIII products other than rFVIIIFc (exception allowed for 
1 emergency or accidental use).  
 If, in the clinical j udgment of the Investigator or Sponsor , it is not in the subject’s best 
interest to continue with the study treatment.  
The reason for the subject’s withdrawal from the study must be recorded in the subject’s 
electronic case report form (eCRF). When a subje ct is withdrawn, the date of study treatment 
dose and the date and reason for treatment/study withdrawal (see above) will be clearly described 
in the relevant sections of the eCRF. If a subject is removed from treatment because of an AE, 
the reason for tre atment withdrawal will be stated as “adverse event” irrespective of whether this 
was the Investigator’s or the subject’s decision. This subject will be followed until the event has 
resolved, stabilized, or returned to baseline.  
The withdrawn subject will b e examined as soon as possible, whenever possible, irrespective of 
the reason for withdrawal. Subjects who are withdrawn will not be replaced. Relevant samples 
will be obtained, and all relevant assessments will be completed, preferably according to the 
schedule for EOT  Visit. The eCRF will be completed as much as possible.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 51 11. STUDY TREATMENT   
The Sponsor will provide rFVIIIFc to sites in all countries.  
11.1. Dosing Regimen and Administrati on  
Refer to and follow the package insert or the Directions for Handling and Administration (DHA). 
See Section  5.4 for the rationale for the selected dosage regimen, dose levels, and treatment 
duration.  
During the ITI Period , the rFVIIIFc dose administered is 200 IU/kg/day (±8 hours), which may 
be given as a once -daily dose or divided into several doses per day. If FVIII activity  levels rise 
above 200  IU/dL, after the inhibitors are negative but before all of the ITI success criteria are 
met, the dose will be adjusted according to Investigator judgment to main tain the FVIII activity  
levels between 100 and 200 IU/dL (see Table 4). 
During the Tapering Period  (with all 3 tolerization success criteria met), the rFVIIIFc dose 
administered will be adjusted according to Investigator judgment based on the FVIII activity  
levels to maintain the FVIII activity  levels between 100 and 200 IU/dL during the initial part of 
the Tapering Period , with the aim of tapering the rFVIII Fc dose  to reach a prophylactic dosing 
regimen within 16 weeks  (4 months) . 
An example of a dose adjustment  schedule after the inhibitor titer has become negative and the 
subject has not met all the criteria for a successful tolerization is shown in Table 4. The dose 
adjustment will be individualized according to each subject’s FVIII activity levels during this 
period.  
Table 4 Example of a Dose Adjustment  Schedule: Negative Inhibitor, Not All Success 
Criteria Met   
Peak FVIII Activity Levels  Dose of rFVIIIFc per Day  
<200  IU/dL  200 IU/kg/day  
≥200  IU/dL  100 IU/kg/day  
Abbreviations:  FVIII=coagulation factor VIII; rFVIIIFc=recombinant coagulation factor VIII Fc fusion protein.  
 
During the Tapering Period  (with all 3 tolerization success criteria met), the aim is to keep FVIII 
activity  levels approximately  between 100 and 200  IU/dL for at least 4  weeks  (1 month) , with 
the aim of tapering the dose to reach the prophylactic dosing regimen within at least 12 weeks 
(3 months) (see Table  5). It is recommended that the entire Tapering Period  be at least 16 weeks  
(4 months) . This schedule is only an example, and each subject’s tapering schedule is left to the 
treating physician’s  discretion.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 52 Table 5 Example of a Dose Tapering Schedule: All 3 Success Criteria Met   
Tapering Period  Dose and Interval  
Weeks 1 to 6  100 IU/kg QD  
Weeks 6  to 12  100 IU/kg QOD  
Weeks 12 to 16  50 IU/kg QOD  
Week [ADDRESS_705271]  50 IU/kg 3 times per week (prophylaxis)  
Abbreviations: QD=once a day; QOD=every other day.  
 
During the Follow -Up Period , the prophylaxis regimen will be adjusted based on clinical 
response and with the goal of keepi[INVESTIGATOR_540935] ≥1 IU/dL at all time points according 
to Investigator judgment and local practice.  
If the subject misses a dose, the Investigator should be notified , and the Investigator will 
determine when the next dose of rFVIIIFc should be taken.  
Bleeding epi[INVESTIGATOR_540936]. Concomitant treatment with by[CONTACT_540987]  (FEIBA) or rFVIIa (NovoSeven) will be allowed during the ITI Period  under certain 
circumstances (see Section  [IP_ADDRESS]  for details).  
11.1.1.  Administration of rFVIIIFc   
After dissolving the powder for injection with the solvent supplied in the pre -filled syringe, 
rFVIIIFc will be delivered via a slow push intravenous (IV) injection over several minutes, at a 
rate of administration determined by [CONTACT_423]’s comfort level.  
Because of the risk of allergic reactions with FVIII concentrates, the initial administration of 
rFVIIIFc will be performed under medical observation, where proper medical care for allergic 
react ions could be provided. Subjects/caregivers will be instructed to administer subsequent 
rFVIIIFc doses at home, except for the dose given prior to assessments of rFVIIIFc t ½ and IR, 
which will be administered in the clinic.  
It is recommended that t he subje ct/caregiver enter dosing information on rFVIIIFc and/or FVIII 
by[CONTACT_540988] a maximum of 7 days , to 
ensure data integrity and to facilitate appropriate medic al review and dosing guidance. Complete 
instructions for the preparation and administration of rFVIIIFc are provided in the DHA within 
the Study Reference Manual . 
11.1.2.  Calculation and Recording of Dosing Based on Actual Potency and Dosing Based on 
Nominal Strength   
Actual potency dosing is required for the dose of 50 IU/kg used to measure IR and t ½ during the 
study . The actual potency shown on the vial must be used to calculate the units of rFVIIIFc and 
the volume to inject.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 53 Note: The instructions and worksheets provided in the DHA must be used to calculate the 
volume for administration based on actual potency. The actual potency shown on the vial must 
be used to calculate the volume for  administration.  
The nominal strength i s defined as the target potency of the vial (i.e., 250, 500, 1000, 2000, or 
3000 IU per vial). Nominal strength will be used for all other rFVIIIFc dose calculations, and 
whole vials will be used to achieve the target dose, rounded to the nearest [ADDRESS_705272]’s welfare, including routine immunizations, may be 
given at the discretion of the Investigator. By[CONTACT_71363] (e.g., aPCC  [FEIBA] or  rFVIIa  
[NovoSeven] ) are allowed in subjects as outlined in Section  [IP_ADDRESS] . All such therapy must be 
recorded in the eCRF. The prophylacti c use of by[CONTACT_540989].  
11.2. Compliance   
Compliance with treatment dosing is to be mo nitored and recorded by [CONTACT_6624].  
The date and time of the rFVIIIFc administrations on Day [ADDRESS_705273]/caregiver in the EPD . The EPD data will be reviewed on an 
ongoing basis by [CONTACT_471608].  
11.3. Excluded Concomitant Therapi[INVESTIGATOR_540937]   
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed from 
30 days prior to the Screening Visit until the Final Safety Follow -Up Visit/Telephone Call. The 
reason for all concomitant procedures performed during the study will be documented in the 
medical records and recorded in the eCRF. AEs related to administration of these procedures 
must be documented on the appropriate eCRF.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 54 No other drug under investigation may be used concomitantly with the study treatment. Subjects 
are not allowed to participate concurrently in another interventional clinical study.  
The following concomitant medications are not permitted during the study:  
 Acetylsalicylic acid  
 Current systemic treatment with chemotherapy and/or other immunosuppressant 
drugs. Use of corticosteroids for the treatment of asthma or management of acute 
allergic epi[INVESTIGATOR_540938] ≥2 mg/kg per day of prednisone or its 
equivalent or ≥20 mg/day if the duration is longer than 14 days.  
 Concomitant im munomodulation will not be allowed during the study.  
 Emicizumab® (Hemlibra)  
 Any other FVIII  
During the Tapering Period , treatment with by[CONTACT_540980] (see Section  7.2.3 ). It is recommended that subjects be 
tested for inhibitors. See Section  [IP_ADDRESS]  for additional details regarding use of by[CONTACT_71363].  
Subjects will be instructed to contact [CONTACT_328927], 
including nonprescription drugs and herbal preparations.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 55 12. STUDY TREATMENT MANAGE MENT   
12.1. rFVIIIFc Stability and Storage   
rFVIIIFc is supplied in kits comprising a single -use vial containing nominally 250, 500, 1000, 
2000, or 3000 IU of factor VIII potency, a pre -filled syringe with 3 mL of sterile water for 
injection, and a sterile vial adapter (reconstitution device). The actual amount of rFVIIIFc in IU 
is stated o n the label and carton of each vial. Any of the potencies listed may be used. The label 
will include conditions for storage, lot number, and other pertinent information such as Sponsor 
and caution statement.  
Study treatment must be stored in a secure locat ion. Accountability for study treatment is the 
responsibility of the Investigator. More details concerning this responsibility are included in 
Section  12.2. 
Study treatment must only be dispensed by a Pharmacist or a medically qualified staff. Study 
treatment is to be dispensed only to a subject (or subject’s legal ly authorized  representative) 
enrolled in this study. Once study treatment is prepared fo r a subject, it can only be administered 
to that subject. Study treatment vials are for 1 -time use only; any study treatment remaining in 
the vial cannot be used for another subject.  
Study site staff will refer to the approved package insert and DHA for sp ecific instructions on the 
handling, preparation, administration, and disposal of the study treatment.  
12.1.1.  rFVIIIFc Preparation   
The individual pr eparing rFVIIIFc will first carefully  review the instructions provided in the 
approved package insert  and the DHA . 
If the packaging is damaged, or if there is anything unusual about the appearance or attributes of 
the vials or drug, it cannot be used. The vial in question will be saved at the  study sit e, and the 
problem will be immediately reported to Sponsor . 
12.1.2.  rFVIIIFc Handling and Disposal   
The Investigator must return all used and unused kits of rFVIIIFc as instruct ed by [CONTACT_540990]. The instructions for returning the kits will be provided at the 
time the request is made by [CONTACT_2728] . 
If any Sponsor  supplies are to be destroyed at the study site, the institution or appropriate site 
personnel must obtain prior approval from Sponsor  by [CONTACT_1541], in writing, the destruction 
policy or details of the method of destruction. After such destruction, the ins titution/Principal 
Investigator(s) must notify Sponsor , in writing, of the details of the study treatment destroyed 
(e.g., lot or kit numbers, quantities), the date of destruction, and proof of destruction.  
 
VV-CLIN-[ADDRESS_705274] 
maintain accurate records demonstrating the date and amount of study treatment received, to 
whom dispens ed (subject -by-subject accounting), amount returned by [CONTACT_423], and accounts 
of any study treatment accidentally or deliberately destroyed. These records will be routinely 
reviewed by [CONTACT_71382].  
Unless otherwise notified, the subject’s parents/legal guardians must return all vials (used and 
unused) at each clinic visit for full medication exchange and accountability. At the end of the 
study, reconciliation must be made between the amount of drug product supplied, dispensed, and 
subsequently destroyed, lost, or returned to Sponsor . A written explanation must be provided to 
Sponsor  for any discrepancies.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 57 13. EFFICACY AND PHARMAC OKINETIC ASSESSMENTS   
Laboratory samples will be drawn for assessment of inhibitor titer (Nijmegen -modified Bethesda 
assay) and FVIII activity (1 -stage activated partial thromboplastin time [aPTT] assay)  and 
analyzed . These samples will be analyzed at the local laboratory and at a central laboratory. The 
Investigators will use  local laboratory results for purposes of decision -making. Bethesda assay 
results are acceptable at sites that have not yet adopted the Nijmegen -modified Bethesda assay. 
Laboratory samples will be obta ined for local assessment of hematology, blood chemistry, and 
urinalysis. Administration of rFVIIIFc, administration of by[CONTACT_71363], occurrence of 
bleed ing epi[INVESTIGATOR_1865] s (spontaneous and traumatic), and associated details will be collected through 
the EPD.  If blood volume sufficient for all samples cannot be drawn, please refer to the Study 
Reference Manual  for a list of prioritization of samples.  
See Section  4.2 for the timing of all assessments.  
13.1. Clinical Efficacy Assessments   
If there is a limitation on blood draw volume, the local laboratory sample will be prioritized. If 
the local laboratory results cannot be interpreted, the Investigator may use the central laboratory 
results.  
Analysis of ITI outcome will be based on the Investigator’s assessment of local laboratory data 
and will be entered into the eCRF. If the local laboratory results cannot be interpreted, the 
Investigator may use the central laboratory results  to assess ITI outcome . 
13.1.1.  Assessment of Inhibitor Titers   
Sampling procedure and bioanalytical method  
Blood samples for the determination of FVIII inhibitors will be collected at all visits during the 
study. The procedures for blood collection, processing into plasma, storing, and transporting to 
the central laboratory ar e fully described in the laboratory section of the Study Reference 
Manual . Samples for inhibitor testing and assessment of FVIII activity  levels will be analyzed at 
the local laboratory and  at a central laboratory . 
Subjects have fulfilled the first criteri a for ITI success after confirmation of negative titers 
consisting of 2 consecutive negative inhibitor assessments within 2 weeks (±3  days) based on 
local laboratory results <0.6 BU/mL by [CONTACT_471597] -modified Bethesda assay; determination of 
negative tite r based on the Bethesda assay is acceptable at sites that have not yet adopted the 
Nijmegen -modified Bethesda assay.  
13.1.2.  Assessment of Incremental Recovery   
[IP_ADDRESS].  FVIII Activity   
A blood sample will be collected for monitoring of FVIII activity  at each visit where IR or t ½ is 
not assessed, starting from Week 2.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 58 Sampling for incremental recovery  
Blood samples will b e collected for analysis of rFVIIIFc activity for assessment of IR starting at 
the visit for confirmed negative titer s and at all consecutive visits , except for those visits at 
which samples for rFVIIIFc t ½ determination are drawn, as IR will be determined from the same 
samples. Samples for IR will be analyzed at the investigational site’s local laboratory  and 
confirmed at the central laboratory, with results being entered into the eCRF. Testing for IR will 
continue , until 2 consecutive assessments represent  ≥66% of the expected  IR (≥1.32 IU/dL per 
IU/kg) . 
Subjects must not be currently bleeding and are required to have at least a 24 -hour washout prior 
to the IR predose sample collection. The sample for IR will be drawn within 30 minutes prior to 
and 30 (±5) minutes after a 50 IU/kg rFVIIIFc injection  administered via a slow push IV 
injection over several minutes, at a rate of administration determined by [CONTACT_423]’s comfort 
level. Volume and units of factor  infused must be calculated and recorded using the actual 
potency as described in the DHA included in the Study Reference Manual . 
According to the local standard of care, an IV access device may be offered to facilitate sample 
collection. Whenever possible , sites are instructed to avoid the use of heparin when drawing PK 
samples. When this is not possible, sites must follow local protocols to ensure heparin is 
adequately removed prior to the PK sample collection. The IV access device must not be flushed 
with heparin between injection of rFVIIIFc and the collection of the samples.  
Once the sample for IR has been collected, the subject s can be given the remainder of their daily 
ITI dose.  
The procedures for blood collection, processing into plasma, storing, and  transporting to the 
central laboratory are fully described in the laboratory section of the Study Reference Manual . 
The plasma samples will be analyzed for FVIII activity at the study’s central laboratory using a 
validated [ADDRESS_705275] fulfilled the second criteri on for ITI success after  achieving  rFVIIIFc IR ≥1.3 2 
IU/dL per IU/kg on 2 consecutive assessments performed within 2 weeks  (±3 days)  (see 
Section  [IP_ADDRESS] ). 
[IP_ADDRESS].  Calculations   
The IR will be calculated as the difference between the FVIII activity  level at 30  ± 5 minutes 
postdose (C 30min) and the FVIII predose activity level (C predose ) divided by [CONTACT_121287], i.e., 
IR = (C30min – Cpredose ) / Dose. Factor VIII activity levels below the lower limit of quantitation 
will be treated as zero. The actual dose of rFVIIIFc will be used t o calculate the IR and t ½. 
Calculations of IR will be done by [CONTACT_540991] . 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 59 13.1.3.  Assessment of rFVIIIFc Half -Life  
[IP_ADDRESS].  Sampling for rFVIIIFc t ½  
Blood samples will be collected for local and central laboratory analys es of rFVIIIFc activity for 
assessment of rFVIIIFc t ½ at the visit after rFVIIIFc IR ≥1.3 2 IU/dL per IU/kg has been 
confirmed  at 2 consecutive assessments performed within 2 weeks  (±3 days) . The assessment 
will be repeated at each consecutive visit until rFVIIIFc t ½ is ≥7 hours and also at the EO T Visit.  
If t½ is <7 hours, subjects need to return to clinic in 2 weeks ( ±3 days ) to complete another t ½ 
assessment until ITI success or 48 weeks (12 months).  t½ determination at EOT Visit does not 
need to be performe d if the complete [ADDRESS_705276] is an ITI Treatment Failure 
(see Section  [IP_ADDRESS] ). 
PK assessment of t ½ requires sampling at multiple timepoints.  During the ITI Period, the 
Investigator may forego the fourth PK sample, i.e., the 30 - or 48 -hour sample, if, in the 
Investigator’s opi[INVESTIGATOR_1649], the t½ at the third PK sample indicates that a t½ ≥[ADDRESS_705277] technique for clearing the infusaport of  
heparin should be employed prior to the 24 - and 30 -/48-hour post-dose samples . Sites are 
advised to refer to their local standard of care regarding maintenance of the IV access device.  
Subjects must not be currently bleeding and are required to have at least a 24 -hour washout prior 
to the rFVIIIFc t ½ predose sa mple collection. A dose of 50 IU/kg of rFVIIIFc for assessments 
will be delivered via a slow push IV injection over several minutes, at a rate of administration 
determined by [CONTACT_423]’s comfort level. Volume and units of factor infused must be calculated 
and recorded using the actual potency  as described in the DHA included in the Study Reference 
Manual . Subjects will not have any additional doses of rFVIIIFc during the PK Sampling Period . 
If emergency dosing is required during the  t½ Sampling Period , inform the Sponsor  and the t½ 
assessment will be rescheduled . 
Once the final sample for t ½ has been collected, the subject s can be given their daily ITI dose.  
Subjects have fulfilled the third and last criteri on for ITI success after a FVIII activity t ½ 
≥7 hours has been determined by [CONTACT_540992]/or central laborator ies (see Section  [IP_ADDRESS] ). 
During the Tapering and Follow -Up Period, if a subject meets the criteria for relapse, he will 
then proceed to the EOT Visit, at which t ½ will be assessed.   
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 60 [IP_ADDRESS].  Calculations   
Calculations of t ½ will be done by [CONTACT_737] /designee and  Sponsor.  Calculations will be 
performed according to the instructions in the DHA included in the Study Reference Manual .  
13.1.4.  Assessment of Bleeding Epi[INVESTIGATOR_1841]   
[IP_ADDRESS].  Definition of a Bleeding Epi[INVESTIGATOR_1865]   
A bleeding epi[INVESTIGATOR_71258] a bleed and ends no more than [ADDRESS_705278] injection of by[CONTACT_540993][INVESTIGATOR_1865], within which any 
symptoms of bleedin g at the same location, injections less than or equal to 72 hours apart, are 
considered the same bleeding epi[INVESTIGATOR_1865]. Any injection of by[CONTACT_540994] (or rFVIIIFc during 
tapering or follow -up) to treat the bleeding epi[INVESTIGATOR_1865], taken more than [ADDRESS_705279]  reports a bleeding epi[INVESTIGATOR_71259], it will be classified as 1 of 2 types: 
spontaneous or traumatic.  
Spontaneous bleeding epi[INVESTIGATOR_540939] a subject or caregiver records a bleeding 
event if there is no known contributing factor such as a definite trauma or antecedent “strenuous” 
activity. The determination of “strenuous” is at the discretion of the Investigator, and the 
parent/caregiver/subject needs to be instructed by [CONTACT_737] . 
Traumatic bleeding epi[INVESTIGATOR_540940] a bleeding 
epi[INVESTIGATOR_71263] a known or believed reason for the bleed. For example, if a subject  
exercises strenuously and then has  a bleeding epi[INVESTIGATOR_71264], the 
bleeding epi[INVESTIGATOR_540941]. Target joint bleeding epi[INVESTIGATOR_97712] a known action led to bleeding into the joint. The Investigator will consider whether 
events resulting in a traumatic bleeding epi[INVESTIGATOR_71267].  
Reporting of bleeding epi[INVESTIGATOR_540942]. However , the 
concomitant events associated with a bleeding epi[INVESTIGATOR_540943] 
(e.g., a n elbow  fracture). Bleeding epi[INVESTIGATOR_71313] a criterion for seriousness will be reported 
as an SAE. All bleeding epi[INVESTIGATOR_540944].  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 61 [IP_ADDRESS].  Data to Be Captured   
It is required that the subject/caregiver enter dosing information on rFVIIIFc and/or FVIII 
by[CONTACT_540995] w ithin a maximum of 7 days , to 
ensure data integrity and to facilitate appropriate medical review and dosing guidance.  
In the event of a bleeding epi[INVESTIGATOR_1865], the following information will be collected i n the EPD  or 
eCRF and medical records:  
 The type of bleedi ng epi[INVESTIGATOR_1865] (i.e., spontaneous or traumatic) and if related to sports 
activity or physical activity  
 The date the bleeding epi[INVESTIGATOR_540945]  
 The product (rFVIIa, aPCCs, FVIII product [include specific drug name], etc.) and 
dose administered to treat the bleed ing epi[INVESTIGATOR_71277]  
 The location of the bleed ing epi[INVESTIGATOR_540946]. Bleeding 
epi[INVESTIGATOR_540947].  
The clinical sites and Clinical Monitors will ensure that there is consistency between the 
subject ’s medical record, dispensing records, source documents, EPD, and eCRFs. During the 
clinic visits, the Investigator will verify whether a bleeding epi[INVESTIGATOR_540948] 
“spontaneous” or “traumatic.” The subject or caregiver will also be reminded about timely EPD 
completion.  
13.2. Medical History Assessments   
Medical, surgical, hemophilia, inhibitor, bleeding  epi[INVESTIGATOR_1865] , and ITI history will be collected at the 
Screening Visit.  
Medical and surgical history includes any significant medical condition and/or any significant 
surgical histories, plus the following: history of allergy/ana phylactic shock, HIV infection status 
(if positive, viral load, CD4 count, and platelets; based on laboratory results within the last 
26 weeks  [6.5 months] ), hepatitis B virus, HCV, medication history, and any other congenital 
immunodeficiency.  
Hemophilia history includes (but is not limited to) the date of diagnosis; severity of disease, 
family history of hemophilia, and genotype; blood group; number of prior exposures to FVIII; 
last dose regimen; and type of FVIII (recombinant, plasma derived with von Wil lebrand factor 
(VWF) or plasma derived without VWF prior to inhibitor development.  
Inhibitor history includes peak historical inhibitor titer, age at the time of inhibitor detection, and 
exposure days at inhibitor development.  
Bleeding epi[INVESTIGATOR_540949] t he 12 months (48 weeks) prior to Baseline includes date, location, 
type of bleeding epi[INVESTIGATOR_1865] (e.g., spontaneous  or traumatic), and treatment of the bleed ing epi[INVESTIGATOR_1865] . 
VV-CLIN-[ADDRESS_705280]’s age at 
Screening, sex, race  and ethnicity (unless not able to be reported due to local regulations) , body 
weight , body length, and geographic location  and will be record ed in the eCRF at the Screening 
Visit. The body weight recording will be repeated at each visit  as specified in the Schedules of 
Activities (see Section  4.2). Height will also be recorded at Screening and EOT Visit.  
13.4. Pharmacoeconomic Assessments   
Consumption will be asses sed based on the amount of administered study treatment as recorded 
in the eCRF and in the EPD . 
The date and time of the in -clinic administrations of rFVIIIFc will be recorded in the eCRF by 
[CONTACT_18370]. The date, time, amount of, and reas on for any study treatment 
administrations done outside the clinic will be recorded by [CONTACT_423]/caregiver in the EPD . 
Subject ’s days missed from school or work will be recorded in the EPD . Hospi[INVESTIGATOR_540950].  
13.5. Exploratory Laborator y Assessments   
VV-CLIN-0542000 3.0

Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 63 
VV-CLIN-0542000 3.0

Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 64 
VV-CLIN-0542000 3.0

Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 65 14.  SAFETY ASSESSMENTS    
See Section  4.2 for the timing of all safety assessments.  
14.1. Clinical Safety Assessments   
The following clinical assessments will be performed to evaluate the safety profile of rFVIIIFc:  
 Physical examinations  
 Vital sign measurements (body temperature, blood pressure, pulse rate, and 
respi[INVESTIGATOR_697] ) should be taken prior to and 20 (±5) minutes after the end of the 
rFVIIIFc injection (i f dosing occurs at the visit)  
 Weight and height measurements  
 Concomitant therapy and procedure recording  
 AE and SAE recording  
14.2. Laboratory Safety Assessments   
Blood samples for dete rmination of hematology and b lood chemistry variables and urine dipstick 
will be collected at Screening  Visit , Baseline Visit (before the first study treatment 
administration), and then every 12 weeks (3 months) from the start of the ITI Period  through the 
time of ITI complete success. These assessments will be collected every 12 weeks (3 months) 
during the Tapering Period . If the subject completes the ITI Period  in a duration shorter than 12 
weeks  (3 months) , these assessments must be completed  at the end of the period. Samples will 
also be collected at the EOT Visit. The date of blood and urine collection will be recorded in the 
eCRF.  
The following laboratory tests will be performed at a local laboratory to assess the safety profile 
of rFVIIIFc : 
 Hematology includes white blood cell count and differential, red blood cell, 
hemoglobin, hematocrit, and platelet count . 
 Blood chemistry includes sodium, potassium, chloride, total protein, total bilirubin, 
gamma glutamyl transferase, aspartate aminotran sferase, alanine aminotransferase, 
alkaline phosphatase, blood urea nitrogen, serum creatinine, and glucose . 
 Dipstick urinalysis, including a protein reading; if the protein reading is positive 
(≥1+), a full laboratory urinalysis will be performed . 
Clinica lly significant abnormal laboratory values should be reported as AEs at the discretion of 
the Investigator. The corresponding result should be entered into the eCRF together with 
information on laboratory variable assessed, date of sample, and normal range  from the local 
laboratory . 
For Canada specific requirements:see Appendix B.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 66  
The volume of blood taken from the subjects: the study -related blood loss should not exceed 3% 
of the total blood volume during a period of 4 weeks (1 month) and should not exceed 1% of the 
total blood volume at any single time (see Table 6 and Section  14.5). 
14.3. Vital Signs   
Vital signs (blood pressure  [systolic and diastolic] , pulse rate, respi[INVESTIGATOR_697], and body 
temperature) will be assessed at each visit. Vital signs should be taken prior to and 20 (±5) 
minutes after the end of the rFVIIIFc inject ion (if dosing occurs at the visit).  
Body temperature will be measured using a tympanic thermometer according to each clinic’s 
standard procedures.  
Abnormal vital sign values  that the Investigator determines are clinically significant  should be 
reported as  AEs (see Section  15.1 for details).  
14.4. Physical Examination   
A general physical examination will be assessed and recorded as “normal” or “ab normal” at each 
visit. Abnormalities will be specified. Any persisting abnormalities will be stated each time the 
examination is performed. Diagnosis of new abnormalities will be recorded as AEs. If any 
abnormalities are reported at the Screening  Visit , they will be recorded as medical history.  
14.5. Sample Volumes   
The volume of blood taken from the subjects should comply with the European Commission 
guidance (European Commission, 2008 ) for recommended blood draw volume limits for 
pediatric patients , that is, the study -related blood loss should not exceed 3% of the total blood 
volume during a period of 4 weeks (1 month) and should not exceed 1 % of the total blood 
volume at any single time. Examples of recommended blood draw volume limits per the 
European Commission guidance are provided in Table 6. Local and/or regional guidelines 
regarding blood draw volumes may also apply.  
Subjects of low body weight may require Screening blood draws over multiple days to comply 
with maximum allowabl e blood draw volumes ( see Table 6). Alternatively, individual 
Investigators may choose to collect all Screening samples using a single blood draw, afte r 
weighing the risk associated with multiple venipuncture attempts versus that of drawing all 
required samples at a single time. If the option of a single blood draw is chosen, the Investigator 
must document the rationale.  
The laboratory section of the Study Reference Manual  will define which laboratory assessments 
to prioritize to ensure that the maximum allowed blood volume is not exceeded.  
VV-CLIN-[ADDRESS_705281] Weight (kg)  Blood Draw Limits (mL)1 
Single Occasion  4 Weeks2 
3.5 2.8 8.4 
4.0 3.2 9.6 
4.5 3.6 10.8 
5.0 4.0 12.0 
5.5 4.4 13.2 
6.0 4.8 14.4 
6.5 5.2 15.6 
7.0 5.6 16.8 
7.5 6.0 18.0 
8.0 6.4 19.2 
8.5 6.8 20.4 
9.0 7.2 21.6 
9.5 7.6 22.8 
10.0 8.0 24.0 
1 Based on an estimated blood volume of 80 mL/kg.  
2 Based on the European Commission guidance (European Commission, 2008 ) for recommended blood draw 
volume limits for pediatric patients, recommending that blood draw volumes not exceed 1% of the total blood 
volume on a single occasion or 3% of the total blood volume  over a 4 -week (1-month) period.  
 
VV-CLIN-[ADDRESS_705282] or his legally authorized representative and/or  main 
caregiver must be given the names and telephone numbers of study site staff for reporting AEs 
and medical emergencies.  
SAEs will be collected from the time of signing ICF to the Final Safety Follow -Up 
Visit/Telephone Call. AEs will be collected from the time of the first dose of rFVIIIFc to the 
Final Safety Follow -Up Visit/Telephone Call.  
See Section  4.[ADDRESS_705283] a causal relationshi p with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not related to the med icinal (investigational) 
product.  
Bleeding epi[INVESTIGATOR_540951]. Bleeding epi[INVESTIGATOR_71313] 
a serious criterion must be reported as an SAE. All bleeding epi[INVESTIGATOR_540952]’s caregivers will be 
maintaining throughout the study period.  EPD data must be entered within 7 days.  
Determination of whether an abnormal laboratory value meets the definition of an AE will be 
made by [CONTACT_14520]. Although abnormal laboratory values are typi[INVESTIGATOR_71310], 
the following considerations may result in an abnormal laboratory value being considered an AE:  
 A laboratory test result that meets the criteria for an SAE  
 A laboratory test r esult that requires the subject to receive specific corrective therapy  
 A laboratory abnormality that the Investigator considers to be clinically significant  
Preexisting Conditions  
A preexisting condition (i.e., a disorder present before the AE reporting pe riod started and noted 
on the pretreatment medical history/physical examination form) should not be reported as an AE , 
unless the condition worsens in severity or epi[INVESTIGATOR_540953].  
VV-CLIN-[ADDRESS_705284] be 
reported if it meets the definition of an AE. For example, an acute appendicitis that b egins during 
the AE reporting period would be reported as the AE and the resulting appendectomy entered in 
the comments section in the eCRF.  
Lack of Efficacy  
If there is a relapse of inhibitor after initial successful ITI , this will be captured as an SAE, 
“relapse of inhibitor” and not as “lack of efficacy .” 
15.1.2.  Serious Adverse Event   
An SAE is any untoward medical occurrence that at any dose:  
 Results in death  
 In the view of the Invest igator, places the subject at immediate risk of death (a 
life-threatening event); however, this does not include an event that, had it occurred 
in a more severe form, might have caused death  
 Requires subject hospi[INVESTIGATOR_296962]  
 Results in persistent or significant disability/incapacity  
 Results in a congenital anomaly/birth defect  
An SAE may also be any other medically important event that, in the opi[INVESTIGATOR_689], 
may jeopardize the subject or may requi re intervention to prevent 1 of the other outcomes listed 
in the definition above. (Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or convulsions occurring at home that do not 
require subjec t hospi[INVESTIGATOR_059].).  
15.2. Safety Classifications   
15.2.1.  Investigator Assessment of Events   
All events must be ass essed to determine the following:  
 If the event meets the criteria of an SAE as defined in Section  15.1.2   
 The relationship of the event to study treatment as defined in Section  15.2.2   
 The s everity of the event as defined in Section  15.2.3 . 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 70 15.2.2.  Relationship of Events to Study Treatment   
The following definitions should be considered when evaluating the rel ationship of AEs and 
SAEs to the study treatment:  
Relationship of Event to Commercial Drug 
Not related  An AE is considered “not related” to the use of the investigational drug if there is not a 
possibility that the event has been caused by [CONTACT_540996]. Factors 
pointing toward this assessment include, but are not limited to: the lack of reasonable 
temporal relationship between administration of the drug and the event, the presence of a 
biologically implausible relationship between the pr oduct and the AE (e.g., the event 
occurred before administration of drug), or the presence of a more likely alternative 
explanation for the AE.  
Related  An AE is considered “related” to the use of the investigational drug if there is a 
possibility that the  event may have been caused by [CONTACT_95107]. 
Factors that point toward this assessment include, but are not limited to: a positive 
re-challenge, a reasonable temporal sequence between administration of the drug and the 
event, a known res ponse pattern of the suspected drug, improvement following 
discontinuation or dose reduction, a biologically plausible relationship between the drug 
and the AE, or a lack of an alternative explanation for the AE.  
Abbreviation : AE=adverse event.  
15.2.3.  Severity o f Events   
The following definitions should be considered when evaluating the severity of AEs and SAEs:  
Severity of Event  
Mild  Symptom(s) barely noticeable to subject or does not make subject uncomfortable; does 
not influence performance or functioning; prescription drug not ordinarily needed for 
relief of symptom(s) but may be given because of personality of subject.  
Moderate  Symptom(s) of a sufficient severity to make subject un comfortable; performance of daily 
activity is influenced; subject is able to continue in study; treatment for symptom(s) may 
be needed.  
Severe  Symptom(s) cause severe discomfort; symptom (s) cause incapacitation or significant 
impact on subject’s daily lif e; severity may cause cessation of treatment with study 
treatment; treatment for symptom(s) may be given and/or subject hospi[INVESTIGATOR_057].  
15.2.4.  Expectedness of Events   
Expectedness of all AEs will be determined by [CONTACT_540997] . 
VV-CLIN-[ADDRESS_705285] dose of study treatment and the 
Safety Follow -Up Visit/Telephone Call is to be recorded on the subject’s eCRF, regardless of the 
severity of the event or its relationship to study treatment.  
15.3.2.  Serious Adverse Events   
Any SAE experienced by a subject between the time of signature [CONTACT_541017] -Up Visit/Telephone Call is to be recorded on an SAE Form, regardless of the severity of 
the event or its relationship to study treatment. SAEs must be reported to IQVIA 
Pharmacovigilance and the designated personnel within [ADDRESS_705286] be reported within 24 hours.  
Bleeding epi[INVESTIGATOR_540954]. However , the 
concomitant events associated with a bleeding epi[INVESTIGATOR_540943] 
(e.g., an elbow fracture). Bleeding epi[INVESTIGATOR_71313] a criterion for seriousness will be reported 
as an SAE. All bleeding epi[INVESTIGATOR_540955].  
Any SAE ongoing when the subject completes the study or discontinues from the study will be 
followed by [CONTACT_71390], stabilized, or returned to Baseline 
status.  
In this study, the following events are considered medically important and must be reported as 
SAEs:  
 Development of a confirmed positive inhibitor ( ≥0.6 BU/mL) after ITI success, 
during the Tapering and Follow -Up Periods  (i.e., relapse of an inhibitor)  
 A subject develops a Grade 2 or greater allergic reaction in association with 
administration of rFVIIIFc defined as follows using the Recommendations for 
Grading of Acute and Subacute Toxic Effects on the World Health Organ ization scale 
(WHO, 1979 ): 
 Grade 2: bronchospasm; no parenteral therapy needed  
 Grade 3: bronchospa sm; parenteral therapy required  
 Grade 4: anaphylaxis  
 A subject develops a vascular thrombotic event, with the exception of IV injection 
site thrombophlebitis  
Allergic reactions, including anaphylaxis, have been reported with FVIII products. The 
subjects/ca regivers must be informed of early symptoms and signs of hypersensitivity reactions, 
including difficulty breathing, chest tightness, swelling of the face, rash, or hives. If such an 
event occurs while the subject is at home, the subjects/caregivers must b e instructed to seek 
immediate medical care.  
VV-CLIN-[ADDRESS_705287] and/or the subject’s legally authorized representatives will be informed of the early 
symptoms and signs of thrombotic phenomena, including pain and/or tenderness along a vein ; 
unexpected swelling of  an arm or leg without pain or tenderness ; redness along a vein ; low fever 
without any known reason (such as a cold or flu) ; sudden shortness of breath , difficulty 
breathing, or coughing ; sudden chest pain ; sudden severe headache or changes in vision ; and 
numbness or tingling in arms or legs. If such an event occurs while the subject is at home, the 
subject and/or the subject’s caregivers will be instructed to seek immediate medical care for the 
subject.  
15.3.3.  Immediate Reporting of Serious Adverse Events   
To adhere to all applicable laws and regulations for reporting an SAE, the study site must 
formally notify IQVIA Pharmacovigilance within 24 hours of the study site staff becoming 
aware  of the SAE. It is the Investigator’s responsibility to ensure that the SAE reporting 
information and procedures are used and followed appropriately.  
Reporting Information for SAEs  
Any SAE that occurs between the time that the subject or subject’s parents/legal guardian 
has signed the ICF and 7  to 14 days after the EOT Visit  (Final Safety Follow -Up 
Visit/Telephone Call) must be reported to IQVIA Pharmacovigilance within [ADDRESS_705288] be s ubmitted regardless of the following:  
 Whether or not the subject has undergone study -related procedures  
 Whether or not subject has received study treatment  
 The severity of the event  
 The relationship of the event to study treatment  
To report initial or follow -up information on an SAE, fax a completed SAE form to IQVIA 
Pharmacovigilance at the country -specific fax numbers provided in the Study Reference 
Manual  Official Contact [CONTACT_71393].  
[IP_ADDRESS].  Deaths   
Death is an outcome of an event. The event that resulted in death should be recorded on the 
appropriate eCRF. All causes of death must be reported as SAEs within [ADDRESS_705289] ed Serious Adverse Reactions   
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) are SAEs that are unexpected and 
judged by [CONTACT_540998] s tudy treatment administered.  
VV-CLIN-[ADDRESS_705290] been done with rFVIIIFc. The effects of rFVIIIFc on 
pregnancy or the offspring of male subjects are unknown. In accordance with regulatory 
guidance, Sponsor  recommends that Investigators discuss the use of contraception with subjects , 
as appropriate . 
For Canada specific changes: See Appendix B.  
15.4.2.  Reporting Pregnancy   
Congenital abnorma lities /birth defects  in the offspring of male subjects will be reported as an 
SAE when study treatment -exposed conception occurs.  
Pregnancy in male subject’s partner shall be reported to IQVIA Pharmacovigilance (at the 
country -specific fax numbers provided  in the Study Reference Manual ) promptly upon 
awareness by [CONTACT_256718], whether associated with an AE or not. Pregnancy itself will 
not be considered an AE. In all reported situations, Sponsor  or designee will provide the 
Investigator with a Pregna ncy Report Form , which shall be completed and returned by [CONTACT_3786]. Sponsor  or designee will make every effort to follow up on the outcome of the 
pregnancy.  
15.4.3.  Overdose   
An o verdose is any dose of study treatment administered to a subject or taken by a subject that 
exceeds the dose assigned to the subject according to the protocol. Overdoses are not considered 
AEs and should not be recorded as an AE on the eCRF; however, all o verdoses must be recorded 
on an Overdose form and faxed to IQVIA Pharmacovigilance within [ADDRESS_705291] the study’s Medical Monitor. See the Study Reference Manual  Official Study Contact 
[CONTACT_71393].  
15.5. Safety Responsibilities   
15.5.1.  Investigator Responsibilities   
The Investigator’s responsibilities include the following (see Section  15.1): 
 Monitor and record all AEs, including SAEs, regardless of the severity or relationship 
to study treatment.  
 Determine the seriousness, relationship, and severity of each event.  
 Determine the onset and resolution dates of ea ch event.  
 Report congenital abnormalities/birth defects in the offspring of male subjects when 
study treatment -exposed conception occurs.  
 Complete an SAE form for each SAE , and fax it to IQVIA Pharmacovigilance within 
24 hours of the study site staff becom ing aware of the event or new information.  
 Ensure that all AE and SAE reports are supported by [CONTACT_71394]’ 
medical records.  
 Pursue AE follow -up information, if possible, until the event has resolved or become 
stable.  
 Report SAEs to local  ethics committees, as required by [CONTACT_1769].  
For Canada specific changes, see Appendix B.  
The Investigator may delegate responsibilities for study -related tasks where appropriate to 
individuals sufficiently qualified by [CONTACT_8640], training, and experience, in accordance with 
International Council for Harmonisation (ICH) - Good Clinical Practice (GCP). The Investigator 
must maintain a list of the appropriately qualified persons to whom significant study -related 
duties have been delegated.  
15.5.2.  Sponsor   
Sponsor ’s responsibilities include the following:  
 Before study site activation and subject enrollment, the Clinical Monitor or designee 
is responsible for reviewing with study site staff the definitions of AE and SAE, as 
well as the instructions for monito ring, recording, and reporting SAEs.  
 Sponsor  is to notify all appropriate regulatory authorities, central ethics committees, 
and Investigators of SAEs, as required by [CONTACT_1769], within required time frames.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 75 16. STATISTICAL METHODS AND DETERMINATION OF  
SAMPLE S IZE  
The objectives of the study and the endpoints to be analyzed are listed in Section  6. 
Detailed methodology for summary and statistical analyses of the data collected in this study will 
be documented in a Statistical Analysis Plan (SAP). In general, continuous variables will be 
summarized by [CONTACT_9086], which includes the number, mean, median, standard 
deviation, minimum, and maximum. Categorical variables and response variables will be 
presented with the number and percentage in each category. Unless otherwise indicated, analysis 
will be performed separately f or the ITI, Tapering , and Follow -Up Periods . No formal statistical 
hypothesis testing using inferential statistics will be performed.  
16.1. Sample Size Considerations   
Because the number of subjects who have severe hemophilia A and developed inhibitors is 
small, the determination of sample size for this study is constrained by [CONTACT_540999]. To describe the duration of time needed to develop tolerization from the onse t of ITI, 
the study plans to prospectively enroll up to  [ADDRESS_705292] time.  
16.2. Efficacy   
16.2.1.  Analysis Populations   
For the purpose of statistical analyses, 3 analysis sets are defined based on the following criteria:  
 ITI Full Analysis Set (ITIFAS): This set will include all subjects receiving at least 
1 infusion of rFVIIIFc. All  analyses describing efficacy and safety during ITI 
treatment will be based on this analysis set . 
 Tapering Period Full Analysis Set (TPFAS): This set will include all subjects entering 
the tapering phase of the study. All analyses describing efficacy and s afety during this 
phase will be based on this analysis set . 
 Follow -Up Period Full Analysis Set: This set will include all subjects entering the 
follow -up phase in the study. All analyses describing efficacy and safety during this 
phase will be based on thi s analysis set . 
16.2.2.  Methods of Analysis   
[IP_ADDRESS].  Primary Endpoint Analysis   
The primary endpoint of this study, time to tolerization  with a maximum of 12 months 
(48 weeks) of ITI treatment , will be summarized descriptively using minimum, mean, standard 
deviation, median, 25th and 75th quartiles, and maximum. A Kaplan -Meier plot showing 
percentage of subjects who are t olerized against time from the first ITI infusion will also be 
generated. Subjects not achieving ITI success during the 12 -month  (48-week) ITI Period  will be 
censored at the last observed time for this analysis. The ITIFAS will be used for this analysis.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 76 Descriptive statistics of the levels of rFVIIIFc inhibitors will be summarized longitudinally for 
all visits during the ITI Period . 
[IP_ADDRESS].  Secondary Endpoints Analysis   
ITI success  
The number and proportion of subjects achieving complete ITI success, partial success, or 
treatment failure will be calculated.  
The ITIFAS will be used for this analysis.  
Occurrence of relapse after successful ITI  
Occurrence of relapse will be summarized descriptively by [CONTACT_541000]. The TPFAS will be used for this analysis.  
Time to relapse will be defined as the duration between ITI success and time of relapse. Time to 
relapse from successful ITI will also be summarized descriptively for subjects who relapsed 
during the Tapering or Follow -Up Period . 
Number of bleeding epi[INVESTIGATOR_540956], Tapering , and Follow -Up Periods  
The number of bleeding epi[INVESTIGATOR_540957]. 
Descriptive statistics for annualized bleeding rate over both Tapering and Follow -Up Periods  
will also be summarized using the TPFAS. The rate for each subject will be annualized to 
account for potential difference in Tapering and Follow -Up Periods . 
Number of days away from work or school  
Number of days missed from school or work will be summarized descriptively for the ITI Period  
using the ITIFAS and for the combined Tapering and Follow -Up Periods  using the TPFAS.  
Numb er of hospi[INVESTIGATOR_540958] -Up Periods  using the TPFAS.  
Adherence  
Adherence with the treatment regimen will be calcu lated in 2 ways : as dose adherence and as 
dosing frequency adherence. Percentage of administered doses as registered in the EPD versus 
the prescribed doses and percentage of number of days with infusions as registered in the EPD 
compar ed with the  prescribe d number of days will be summarized using descriptive statistics for 
each of the 3 periods separately.  
Consumption during ITI  
Consumption during the entire study will be summarized descriptively using the ITIFAS. 
Descriptive statistics will also be provide d for each of the periods separately using their 
respective analysis set.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 77 [IP_ADDRESS].  Pharmacokinetics   
Data listings based on local and central laboratory results of IR and/or t ½ for each subject by [CONTACT_541001].  
[IP_ADDRESS].  Exposure and Duration of Treatment   
Duration of exposure and the total number of exposure days (EDs) to rFVIIIFc will be 
summarized descriptively.  An ED is a 24 -hour period in which 1 or more rFVIIIFc injections are 
given.  
[IP_ADDRESS].  Demography and Baseline Disease Characteristics   
Demographics and baseline characteristics will be sum marized with descriptive statistics.  
16.3. Interim Analyses   
An interim analysis is planned for when at least [ADDRESS_705293]  24 weeks 
(6 months ) of ITI trea tment. Subsequent interim analyses will depend on the number of years 
required to recruit the targeted number of subjects.   
16.4. Safety   
16.4.1.  Analysis Populations   
See Section  16.2.1 . 
16.4.2.  Methods of Analysis   
[IP_ADDRESS].  Adverse Events   
Reported AEs during the study will be coded using Medical Dictionary for Regulatory Activities. 
The number and percentage of subjects with any AEs occurring after the first infusion of 
rFVIIIFc will be summarized in frequency tables by [CONTACT_6764], prefer red term, and maximum 
severity. Listings of serious SAEs and AEs leading to discontinuation will also be presented.  
Tabulations of AEs and SAEs will be made separately for the ITI Period , the Tapering and 
Follow -Up Periods  combined, as well as all 3 period s combined using ITIFAS and TPFAS, 
respectively. Tabulation for all AEs by [CONTACT_541002].  
[IP_ADDRESS].  Clinical Laboratory Results   
Listings of abnormal  laboratory test results will be provided.  
[IP_ADDRESS].  Vital Signs   
Vital signs will be summarized by [CONTACT_541003]. Abnormal va lues will be defined in the SAP. A listing of abnormal vital signs will 
be provided.  
VV-CLIN-[ADDRESS_705294] not be altered without the agreement of the relevant ethics 
committee and Sponsor . 
It is the responsibility of the Investigator(s) to ensure that all aspects of institut ional review are 
conducted in accordance with current governmental regulations.  
Sponsor  must receive a letter documenting ethics committee approval, which specifically 
identifies the protocol, tracking number, and ICF version, prior to the initiation of th e study. 
Protocol amendments will be subject to the same requirements as the original protocol.  
A progress report must be submitted to the ethics committee at required intervals and not less 
than annually. Documentation of the submission must be provided t o Sponsor . 
At the completion or termination of the study, the investigational site must submit a close -out 
letter to the ethics committee and Sponsor . 
17.3. Subject Information and Consent   
Prior to performing any study -related activities under this protocol, including Screening tests and 
assessments, written informed consent with the approved ICF must be obtained from the subject 
or subject’s legally authorized representative, as applic able, in accordance with local practice and 
regulations.  
The background of the proposed study, the procedures, the benefits and risks of the study, and 
that study participation is voluntary for the subject must be explained to the subject (or the 
VV-CLIN-[ADDRESS_705295]’s  legally authorized representative). The subject must be given sufficient time to consider 
whether to participate in the study.  
Subjects will be informed that their race and ethnicity will be collected and will be used during 
analysis of study results  (unless not able to be reported due to local regulations)  (see 
Section  17.4). 
In addition, pediatric subjects who have the capacity should provide their assent to participate in 
the study. The level of information provided to subjects should match their level of 
understanding as determined by [CONTACT_541004].  
A copy of the signed and dated ICF ( and assent, if applicable) must be given to the subject or the 
subject’s legally authorized representative. Confirmation of a subject’s informed consent must 
also be documented in the subject’s medical record prior to any testing under this protocol, 
inclu ding Screening tests and assessments.  
Local regulations must be complied with in respect to the final disposition of the original (wet 
signature) ICF and of copi[INVESTIGATOR_71323]. The original signed ICF will be 
retained with the study record s. 
17.4. Subject Data Protection   
Prior to any testing under this protocol, including Screening tests and assessments, candidates 
must also provide all authorizations required by [CONTACT_1769] (e.g., protected health information 
authorization in North America).  
During the study, the subjects’ race and ethnicity will be collected. In cross sectional analyses of 
different ethnic groups, differences in the occurrence of inhibitors have been obs erved 
(Astermark et al., 2005 ; Carpenter et al., 2012 ). Differential responses to FVIII products may 
occur in different haplotypes of FVIII that also differ across racial and ethnic groups (Viel et al., 
2009 ). 
Study reports will be used for research purposes only. The subject will not be identified by [CONTACT_441130], study -related forms, study reports, or any related publications. Sponsor , its partners 
and designees, ethics committees, and various government heal th agencies may inspect the 
records of this study. Every effort will be made to keep the subject’s personal medical data 
confidential.  
17.5. Compensation for Injury   
Sponsor  maintains a ppropriate insurance coverage for clinical studies and will follow applicable 
local compensation laws.  
17.6. Conflict of Interest   
The Investigators will address any potential conflicts  of interest (e.g., financial interest in the 
Sponsor) with the subject before the subject decides to participate in the study.  
VV-CLIN-[ADDRESS_705296] not screen any subjects prior to completion of a study initiation visit, 
conducted  by [CONTACT_541005]. The initiation visit 
will include a detailed review of the protocol and study procedures.  
18.2. Quality Assurance   
During and/or after completion of the study,  quality assurance officers named by [CONTACT_541006] -site audits. The Investigator will be expected to 
cooperate with any audit and to provide assistance and documentation (including source data) as 
requested.  
18.3. Monitoring of the Study   
Sponsor  or its designee will conduct on -site visits at the study facilities to monitor various 
aspects of the study. The Investigator must agree to Sponsor -authorized personnel having direct 
access to subject (or associated) files to verify entries made in the eCRF. Adequate space and 
time for monitoring visits must be made available by [CONTACT_80476]. The site 
must complete the eCRFs in a t imely manner and on an ongoing basis to allow regular review by 
[CONTACT_3476].  
18.4. Study Funding   
This study is designed and financed by [CONTACT_541007]. Bioverativ is the Sponsor of the study and is funding the study with Sobi. All 
financial details are provided in the separate contract(s) between the institution, Investigator, and 
Sponsor.  
18.5. Publications   
Details are included in the clinical trial agreement for this study.  
VV-CLIN-[ADDRESS_705297] information will be captured and managed by [CONTACT_71408] a Web -based 
electronic data capture (EDC) tool developed and supported by [CONTACT_541008] . It is recommended that data be entered into the 
EDC tool within 5 business days, including batched records and records with source documents.  
Subjects  and/or his  parents/caregivers in the study will have EPDs to record information 
regarding each dose of rFVIIIFc administered to the subject for any reason.  EPD data must be 
entered  within 7  days ( see Section  [IP_ADDRESS]  ). Entries will be made in EPD for at -home 
administration and in the eCRF for in -clinic/scheduled visit administration.  
19.1.4.  Central Laborator y for Assessments   
Laboratory samples will be drawn for assessment of inhibitor titer (Nijmegen -modified Bethesda 
assay or Bethesda assay at sites that have not yet adopted the Nijmegen -modified assay) , FVIII 
activity (1 -stage aPTT assay)  for IR and t ½, immune cell characterization, viral analysis, optional 
analysis of FVIII mutation and HLA allotypi[INVESTIGATOR_007] . These samples will be analyzed at the local 
laboratory and the central laboratory. The Investigators will use local laboratory results for 
purposes of decision -making.  
19.2. Study Committees   
Not applicable.  
19.3. Changes to Final Study Protocol   
All pr otocol amendments must be submitted to the ethics committee and Regulatory Authorities 
if required by [CONTACT_1769]. Protocol modifications that affect subject safety, the scope of the 
investigation, or the scientific quality of the study must be approved by t he ethics committee 
before implementation of such modifications to the conduct of the study. If required by [CONTACT_541009]-CLIN-[ADDRESS_705298] consent form may require similar 
modifications (see Section  17.3). 
19.4. Ethics Committee Notification of Study Completion or Termination   
Where required, the health authorities and ethics committees must be notified of completion or 
termination of this study and sent a copy of the study synopsis in accordance with necessary 
timelines.  
19.5. Retention of Study Data   
The minimum retention time for study records will meet the strictest standard applicable to that 
site, as dictated by [CONTACT_65406] . Prior to proceeding 
with destruction of records, the Investigator must notify Sponsor  in writing and receive written 
authorization from Sponsor  to destroy study records. In addition, the Investigator must notify 
Sponsor  of any changes in the archival arr angements including, but not limited to, archival at an 
off-site facility or transfer of ownership if the Investigator leaves the site.  
19.6. Study Report Signatory   
Sponsor  will design ate one of the participating Study Investigators as a signatory for the study 
report. This determination will be made by [CONTACT_71411], including, but not limited to, the 
Investigator's experience and reputation in the studied indication; the Investigato r's contribution 
to the study in terms of design, management, and/or subje ct enrollment; or by [CONTACT_541010] . 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 85 20. REFERENCES   
Astermark, J., Oldenburg, J., Escobar, M., White, G. C., Berntorp, E., & group, M. I. B. S. s. 
(2005). The Malmö International Brother Study (MIBS). Genetic defects and inhibitor 
development in siblings with severe hemophilia A. Haematologica, 90 (7), 924 -931.  
Caram, C., de Souza, R. G., de Sousa, J. C., Araujo Pereira, T., do Amaral Cerqueira, A. M., van 
der Bom, J. G., et al. (2011). The long -term course of factor VIII inhibitors in patients 
with congenital haemophilia A without immune tolerance induction. Thromb Haemost, 
105(1), 59 -65. doi:10.1160/TH10 -04-0231  
Carcao, M., Shapi[INVESTIGATOR_2152], A., Staber, J., Hwang, N., Druzgal, C., Lieuw, K., et al. (2017). rFVIIIFc 
for Immune Tolerance Induction in Severe Hemophilia A Patients with Inhibitors - A 
Retrospective Analysi s- Poster LB 04. ISTH .  
Carpenter, S. L., Michael Soucie, J., Sterner, S., Presley, R., & Investigators, H. T. C. N. H. 
(2012). Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A 
enrolled in the Universal Data Collection data base. Haemophilia, 18 (3), e260 -265. 
doi:10.1111/j.1365 -2516.2011.[ZIP_CODE].x  
Coppola, A., Margaglione, M., Santagostino, E., Rocino, A., Grandone, E., Mannucci, P. M., et 
al. (2009). Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance 
induction of hemophilia A patients with high -responding inhibitors. J Thromb Haemost, 
7(11), 1809 -1815. doi:10.1111/j.1538 -7836.2009.[ZIP_CODE].x  
Damiano, M. L., & Hutter, J. J ., Jr. (2000). Immune tolerance for haemophilia patients with 
inhibitors: analysis of the western [LOCATION_002] experience. The Tri -Regional Nursing 
Group. Haemophilia, 6 (5), 526 -532.  
De Groot, A. S., Moise, L., McMurry, J. A., Wambre, E., Van Overtvelt, L., Moingeon, P., et al. 
(2008). Activation of natural regulatory T cells by [CONTACT_541011] -derived peptide "Tregitopes". 
Blood, 112 (8), 3303 -3311. doi:10.1182/blood -2008 -02-138073  
Dimichele, D. (2009). The North American Immune Tolerance Registry: contributions to the 
thirty -year experience with immune tolerance therapy. Haemophilia, 15 (1), 320 -328. 
doi:10.1111/j.1365 -2516.2008.[ZIP_CODE].x  
DiMichele, D. M., Kroner, B. L., & North Americ an Immune Tolerance Study, G. (2002). The 
North American Immune Tolerance Registry: practices, outcomes, outcome predictors. 
Thromb Haemost, 87 (1), 52 -57.  
European Commission. (2008). Ethical considerations for clinical trials on medicinal products 
conduc ted with the paediatric population. In.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 86 Franchini, M., Coppola, A., Rocino, A., Santagostino, E., Tagliaferri, A., Zanon, E., et al. (2013). 
Systematic review of the role of FVIII concentrates in inhibitor development in 
previously untreated patients with severe hemophilia a: a [ADDRESS_705299], 39 (7), 752 -766. doi:10.1055/s -0033 -1356715  
Franchini, M., & Lippi, G. (2011). Immune tolerance induction for patients with severe 
hemophilia A: a critical literature review. J Thromb Thrombolysis, 32 (4), 439 -447. 
doi:10.1007/s11239 -011-0624 -3 
Gouw, S. C., van der Bom, J. G., Ljung, R., Escuriola, C., Cid, A. R., Claeyssens -Donadel, S., et 
al. (2013). Factor VIII products and inhibitor development in severe hemophilia A. N 
Engl J Med, 368 (3), 231 -239. doi:10.1056/NEJMoa1208024  
Gringeri, A. (2007). VWF/FVIII concentrates in high -risk immunotolerance: the RESIST study. 
Haemophilia, [ADDRESS_705300] 5 , 73-77. doi:10.1111/j.1365 -2516.2007.[ZIP_CODE].x  
Groomes, C. L., Gianferante, D. M., Crouch, G. D., Parekh, D. S., Sco tt, D. W., & Lieuw, K. 
(2016). Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction 
With Recombinant Factor VIII -Fc Fusion Protein. Pediatr Blood Cancer, 63 (5), 922 -924. 
doi:10.1002/pbc.[ZIP_CODE]  
Gupta, N., Culina, S., Meslier, Y., Dimit rov, J., Arnoult, C., Delignat, S., et al. (2015). 
Regulation of immune responses to protein therapeutics by [CONTACT_541012] T 
cell tolerance. Sci Transl Med, 7 (275), 275ra221. doi:10.1126/scitranslmed.aaa1957  
Hay, C. R., DiMichele, D. M., & In ternational Immune Tolerance, S. (2012). The principal 
results of the International Immune Tolerance Study: a randomized dose comparison. 
Blood, 119 (6), 1335 -1344. doi:10.1182/blood -2011 -08-369132  
Hay, C. R. M., & DiMichele, D. M. (2012). The principal res ults of the International Immune 
Tolerance Study: a randomized dose comparison. Blood, 119 (6), 1335 -1344. 
doi:10.1182/blood -2011 -08-369132  
Haya, S., López, M. F., Aznar, J. A., Batlle, J., & Group, S. I. T. (2001). Immune tolerance 
treatment in haemophilia  patients with inhibitors: the Spanish Registry. Haemophilia, 
7(2), 154 -159.  
Hofbauer, C. J., Kepa, S., Schemper, M., Quehenberger, P., Reitter -Pfoertner, S., Mannhalter, C., 
et al. (2016). FVIII -binding IgG modulates FVIII half -life in patients with seve re and 
moderate hemophilia A without inhibitors. Blood, 128 (2), 293 -296. doi:10.1182/blood -
2015 -10-675512  
Hofbauer, C. J., Whelan, S. F., Hirschler, M., Allacher, P., Horling, F. M., Lawo, J. P., et al. 
(2015). Affinity of FVIII -specific antibodies reveals  major differences between 
neutralizing and nonneutralizing antibodies in humans. Blood, 125 (7), 1180 -1188. 
doi:10.1182/blood -2014 -09-598268  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 87 ISTH Factor VIII/IX Scientific Subcommittee (SSC) Working Party on Definitions in 
Hemophilia. (2011). ISTH Consensu s Definitions in Hemophilia [draft]. Updated July 14, 
2011. In.  
Jimenez -Yuste, V., Oldenburg, J., Rangarajan, S., Peiro -Jordan, R., & Santagostino, E. (2016). 
Long -term outcome of haemophilia A patients after successful immune tolerance 
induction therapy u sing a single plasma -derived FVIII/VWF product: the long -term ITI 
study. Haemophilia, 22 (6), 859 -865. doi:10.1111/hae.[ZIP_CODE]  
Kempton, C. L., & Meeks, S. L. (2014). Toward optimal therapy for inhibitors in hemophilia. 
Blood, 124 (23), 3365 -3372. doi:10.1182/blood -2014 -05-577643  
Kreuz, W., Escuriola Ettingshausen, C., Vdovin, V., Zozulya, N., Plyushch, O., Svirin, P., et al. 
(2016). First prospective report on immune tolerance in poor risk haemophilia A inhibitor 
patients with a single factor VIII/ von Willebrand factor concentrate in an observational 
immune tolerance induction study. Haemophilia, 22 (1), 87 -95. doi:10.1111/hae.[ZIP_CODE]  
Kreuz, W., Escuriola Ettingshausen, C., Vdovin, V., Zozulya, N., Plyushch, O., Svirin, P., et al. 
(2016). First prospec tive report on immune tolerance in poor risk haemophilia A inhibitor 
patients with a single factor VIII/von Willebrand factor concentrate in an observational 
immune tolerance induction study. Haemophilia, 22 (1), 87 -95. doi:10.1111/hae.[ZIP_CODE]  
Krishnamoorthy,  S., Liu, T., Drager, D., Patarroyo -White, S., Chhabra, E. S., Peters, R., et al. 
(2016). Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity 
and induces tolerance in hemophilia A mice. Cell Immunol, 301 , 30-39. 
doi:10.1016/j.cellim m.2015.12.008  
Kroner, B. L. (1999). Comparison of the international immune tolerance registry and the North 
American immune tolerance registry. Vox Sang, [ADDRESS_705301] 1 , 33-37. doi:[ZIP_CODE]  
Kurth, M., Puetz, J., Kouides, P., Sanders, J., Sexauer, C., Bernstein, J ., et al. (2011). The use of 
a single von Willebrand factor -containing, plasma -derived FVIII product in hemophilia A 
immune tolerance induction: the US experience. J Thromb Haemost, 9 (11), 2229 -2234. 
doi:10.1111/j.1538 -7836.2011.[ZIP_CODE].x  
Lei, T. C., & Scott , D. W. (2005). Induction of tolerance to factor VIII inhibitors by [CONTACT_541013] A2 and C2 domains presented by B cells as Ig fusion proteins. 
Blood, 105 (12), 4865 -4870. doi:10.1182/blood -2004 -11-4274  
Lissitchkov, T., Hampton, K., von D epka, M., Hay, C., Rangarajan, S., Tuddenham, E., et al. 
(2015). Novel, human cell line -derived recombinant factor VIII (human -cl rhFVIII; 
Nuwiq(®) ) in adults with severe haemophilia A: efficacy and safety. Haemophilia . 
doi:10.1111/hae.[ZIP_CODE]  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 88 Malec, L. M.,  Journeycake, J., & Ragni, M. V. (2016). Extended half -life factor VIII for immune 
tolerance induction in haemophilia. Haemophilia, 22 (6), e552 -e554. 
doi:10.1111/hae.[ZIP_CODE]  
Malec, L. M., Ragni, M. V., Journeycake, J. M., & Alabek, M. (2015). Immune Toleranc e 
Induction Using Rfviiifc (Eloctate). Blood, 126 (23), 3531 -3531.  
Mariani, G., Ghirardini, A., & Bellocco, R. (1994). Immune tolerance in hemophilia -principal 
results from the International Registry. Report of the factor VIII and IX Subcommittee. 
Thromb H aemost, 72 (1), 155 -158.  
Nakar, C., Manco -Johnson, M. J., Lail, A., Donfield, S., Maahs, J., Chong, Y., et al. (2015). 
Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase 
overall success in haemophilia A complicated by  [CONTACT_8292]: experience of two U.S. 
centres. Haemophilia, 21 (3), 365 -373. doi:10.1111/hae.[ZIP_CODE]  
Oldenburg, J., Jimenez -Yuste, V., Peiro -Jordan, R., Aledort, L. M., & Santagostino, E. (2014). 
Primary and rescue immune tolerance induction in children and adults: a multicentre 
international study with a VWF -containing plasma -derived FVIII concentrate. 
Haemophilia, 20 (1), 83 -91. doi:10.1111/hae.[ZIP_CODE]  
Oldenburg, J., & Pavlova, A. (2006). Genetic risk factors for inhibitors to factors VIII and IX. 
Haemophilia, 12 (Suppl 6), 15 -22. doi:10.1111/j.1365 -2516.2006.[ZIP_CODE].x  
Scalone, L., Mantovani, L. G., Mannucci, P. M., Gringeri, A., & Investigators, C. S. (2006). 
Quality of life is associated to the orthopaedic status in haemophilic patients with 
inhibitors. Haemophilia, 12 (2), 154 -162. doi:10.1111/j.1365 -2516.2006.[ZIP_CODE].x  
SmPC. Elocta (INN -efmoroctocog alfa) [sum mary of product Characteristics]. 2015. Biogen, 
Inc., Cambridge, MA.  
Srivastava, A., Brewer, A. K., Mauser -Bunschoten, E. P., Key, N. S., Kitchen, S., Llinas, A., et 
al. (2012). Guidelines for the management of hemophilia. Haemophilia , e1-47. 
doi:10.1111/ j.1365 -2516.2012.[ZIP_CODE].x  
Tagariello, G., Iorio, A., Matino, D., Belvini, D., Salviato, R., Sartori, R., et al. (2013). High rate 
of spontaneous inhibitor clearance during the long term observation study of a single 
cohort of 524 haemophilia A patients not undergoing immunotolerance. J Hematol 
Oncol, 6 , 63. doi:10.1186/[ADDRESS_705302] recent 
version is available at: 
https://www.eloctate.com/_assets/pdf/eloctate_pi_january2017 .pdf.  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 89 Valentino, L. A., Kempton, C. L., Kruse -Jarres, R., Mathew, P., Meeks, S. L., Reiss, U. M., et al. 
(2015). US Guidelines for immune tolerance induction in patients with haemophilia a and 
inhibitors. Haemophilia, 21 (5), 559 -567. doi:10.1111/hae.[ZIP_CODE]  
Viel, K. R., Ameri, A., Abshire, T. C., Iyer, R. V., Watts, R. G., Lutcher, C., et al. (2009). 
Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med, 360 (16), 1618 -
1627. doi:10.1056/NEJMoa075760  
Walsh, C. E., Soucie, J. M., Miller, C. H., & Network, U. S. H. T. C. (2015). Impact of inhibitors 
on hemophilia A mortality in the [LOCATION_002]. Am J Hematol, 90 (5), 400 -405. 
doi:10.1002/ajh.[ZIP_CODE]  
Whelan, S. F., Hofbauer, C. J., Horling, F. M., Allacher, P., Wolfsegger, M. J., Oldenburg, J., e t 
al. (2013). Distinct characteristics of antibody responses against factor VIII in healthy 
individuals and in different cohorts of hemophilia A patients. Blood, 121 (6), 1039 -1048. 
doi:10.1182/blood -2012 -07-444877  
White, G. C., 2nd, Rosendaal, F., Aledort,  L. M., Lusher, J. M., Rothschild, C., Ingerslev, J., et 
al. (2001). Definitions in hemophilia. Recommendation of the scientific subcommittee on 
factor VIII and factor IX of the scientific and standardization committee of the 
International Society on Throm bosis and Haemostasis. Thromb Haemost, 85 (3), 560.  
WHO. (1979). WHO handbook for reporting results of cancer treatment.  WHO Offset 
Publication No. 48. In (pp. 1 -46). Geneva, Switzerland: World Health Organization.  
 
VV-CLIN-[ADDRESS_705303] read the foregoing protocol, “ A Non -Controlled, Open -Label, Multicenter, Study of 
Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophili a A Subjects 
With Inhibitors Undergoing the First ITI Treatment ” and agree to conduct the study according to 
the protocol and the applicable ICH -GCP guidelines and local regulations, and to inform all who 
assist me in the conduct of this study of their res ponsibilities and obligations.  
 
 
 
____________________________________________________  
Investigator’s Signature     [CONTACT_1782]  
____________________________________________________  
Investigator’s Name (Print)  
 
 
 
____________________________________________________  
Study Site (Print)  
  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 91 APPENDIX  A. PROTOCOL AMENDMENT H ISTORY   
The “Protocol Amendment Summary of Changes Table” for the current amendment is located at 
the start of this document (after title  page).  
 
The primary reason for this amendment to Protocol 997HA402 (version  3.0) is to reduce the 
number of subjects to be enrolled, to clarify the timing for subjects moving from interim ITI 
visits to ITI outcome assessment visits, and to clarify sample collection schedules for ADA. 
Additional updates have been made for Canada and these country -specific changes are outlined 
in Appendix  B. 
 
Previous global and country -specific amendments are outlined below.  
 
Protocol Version 1.1 (specific for Canada)   
Protocol Version 1.1 
(from Version 1.0)  New texts were added to the following sections:  
Section 8.1, Section 15.5.1    The primary reason for this 
amendment   to Protocol 997HA402 
was to add the Inclusion Criterion #5 
in response to Health Canada 
Question #[ADDRESS_705304] 
fertility or sperm development in 
hemophilia A patients.This was 
addressed by [CONTACT_541014] #5.  
This change also affected the 
Informed Consent Form, which has 
been updated accordingly.  
The amendment summary 
describing every change i s available 
upon request.  
 
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 92 Protocol Version 2.0 (Global, except Canada)   
Protocol Version 2  
(from Version 1.0)  The changes were introduced in the following sections:  
Synopsis, Section 4.1, Section 4.2.1, Section 5, Section 
6.1, Section 6.2, Section 6.3, Section 7, Section 8.1, 
Section 8.2, Section 9.1, Section 9.2, Section 11, 
Section 12.1, Section 13, Section 14, Section 15, 
Section 16, Section 17, Section 18, Section  19, and in 
Table 1, Table 2, Table 3 and new Section [IP_ADDRESS], 
Section [IP_ADDRESS] and Section 7.2.[ADDRESS_705305].  
 
Protocol Version 2.1 (specific for Canada)   
Protocol Version 2.1 
(from Version 1.1)  The changes were introd uced in the following 
sections/tables:  
Synopsis, Section 4.1, Section 4.2.1, Section 5, Section 
6.1, Section 6.2, Section 6.3, Section 7, Section 8.1, 
Section 8.2, Section 9.1, Section 9.2, Section 11, 
Section 12.1, Section 13, Section 14, Section 15, 
Section 16, Section 17, Section 18, Section 19, and in 
Table 1, Table 2, Table 3 and new sections, Section 
[IP_ADDRESS], Section 7.2.3, Section [IP_ADDRESS], Section 
[IP_ADDRESS], Section [IP_ADDRESS], Section [IP_ADDRESS], Section 
13.5.5, Section 15.4.1, Section 16.[ADDRESS_705306] .  
 
  
VV-CLIN-0542000 3.0
Protocol 997HA402  Version 3.0  
rFVIIIFc Immune Tolerance Induction Study  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of  
Bioverativ Therapeutics Inc.  
Page 93 APPENDIX  B. COUNTRY SPECIFIC REQ UIREMENTS   
 
Country -specific requirements for Canada   
Compared to the global prolocol, the country specific changes  for Canada  are underlined (for aditions)  
or skriked out (for deletions).  
1. Changes in Protocol Vers ion 3  
Section 4.2 (Table 1, footnote 7) and Section 13.5.4  
This assessment is optional, and requires a separate ICF. For subjects whose FVIII mutation and human 
leukocyte antigen (HLA) allotype is not documented in medical records, samples for  analysis of FVIII 
mutation  and HLA allotypi[INVESTIGATOR_540959] . If subject or subject’s legally authorized representative 
consents, samples for analysis will  To be collected at the Baseline Visit or at any subsequent visit if blood 
volume is limited at the Baseline Visit for analysis at the central laboratory . 
Section 4.2 (Table 2, footnote 1)  
During the Tapering and Follow -Up Periods, the subject's dose will be adjusted to achieve each subject's 
prophylactic dose as determined by [CONTACT_737]. Minimum Tapering Period is 16 weeks (4 months). 
Subjects who relapse during the Tapering Period (i.e., who have confirmation of inhibitor development 
AND who have confirmed decrease of IR, with or without clinical signs or symptoms) will proceed 
immediately to the EOT Visit where t 1/[ADDRESS_705307] meet the following eligibility criteria at the 
time of enrollment:  
1. Ability of the subject or his legally authorized representative (e.g., parent or legal guardian) to 
understand the purpose and risks of the study and provide signed and dated informed consent and 
authorization to use protected health information in accordance with national and local subject 
privacy regulations  
2. Male subjects of any age diagnosed with severe hemophilia A (as confirmed from the medical 
record)  
3. Currently diagnosed with high -titer inhibitors (historical peak ≥5 BU/mL , according to medical 
records)  
4. Previously treated with any pd -FVIII or recombinant conventional or Extended Half -Life FVIII  
5. If the subject is fertile and has a female partner of childbearing potential, the subject and partner 
must use effective contracept ion during the study and continue contraception for [ADDRESS_705308] dose of study treatment.  
 
Section 1 5.5.1  
 Monitor and record all A Es, including SAEs, regardless of the severity or relationship to 
study treatment.  
 Determine the seriousness, relationship, and severity of each event.  
 Determine the onset and resolution dates of each event.  
 Report congenital abnormalities/birth defects in  the offspring of male subjects when study 
treatment -exposed conception occurs.  
 Report pregnancy in the partner of a male subject when study -treatment -exposed conception 
occurs, whether or not the pregnancy is associated with an AE.  
 Complete an SAE form fo r each SAE, and fax it to IQVIA Pharmacovigilance within 
24 hours of the study site staff becoming aware of the event or new information.  
 Ensure that all AE and SAE reports are supported by [CONTACT_71394]’ medical 
records.  
 Pursue AE follow -up information, if possible, until the event has resolved or become stable.  
 Report SAEs to local ethics committees, as required by [CONTACT_1769].  
 
 
VV-CLIN-0542000 3.0